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ABSTRACT 
SYNTHESIS OF PEPTIDES WITH HYDROXAMIC ACID SIDE CHAIN 
APPENDAGES 
Yingchuan Susan Sun 
April 14, 2003 
Chapter 1 detailed the synthesis method of hydroxamate peptides derivatives of 
pentapeptide Ac-PHSXX'-N-NH2 by solid phase hydroxamate peptide synthesis method. 
The glutamic acid / aspartic acid side chain was modified to hydroxamic acid by on resin 
N-C coupling. The hydroxamate benzyl protecting group was removed during HF 
cleavage. In Chapter 2 a novel multiple hydroxamic acid peptide siderophore was prepared 
and the metal binding activity of these peptides was studied by ESI-MS and MS/MS. 
Siderophore peptide Ac-GlYI-Glu2(NHOH)-D-Pro3-GlY4-Glus(NHOH)-D-Pr06-NH2 was 
found to have significant preference to Fe(IH) over Zn(H) and Ni(II), while the natural 
peptide analogue Ac-GlYI-Glu2-D-Pro3-GlY4-Glus-D-Pro6-NH2 did not show any obvious 
preference in these metal ions. The study of these multi hydroxamate ligands metal 
coordination revealed that the C-terminal binding site (Glus(NHOH)) has the stronger 
chelation capability than the N terminal (Glu2(NHOH)) metal binding site and the amide 
bonds between glutamic acid and proline were identified as the most fragile bonds by 
MS/MS study. 
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CHAPTER I 
DESIGN AND SYNTHESIS OF HYDROXAMIC ACID VARIANTS OF ANTI-
TUMORIGENIC AND ANTIMETASTATIC AC-PHSXX'-NH2 SEQUENCES 
A Introduction 
1. Biological Importance of Peptide PHSRNI PHSCN 
The adhesive protein fibronectin (FN) is abundant in extracellular matrix of many 
cell types and plays important roles in a variety of biological processes. FNs have been 
shown to be involved in cell adhesion, cell morphology, thrombosis, cell migration, and 
embryonic differentiation (Hynes, 1990). FNs interact with cells using specific domains 
that are bound by specific cell surface receptors. For example, FNs have nearly a dozen 
cell-binding sites that can be recognized and are bound by cell-surface integrin, and this 
process mediates the adhesion of cells to FN in the extracellular matrix. One of the best 
characterized integrin-ligand interactions is a5~1 binding to fibronectin (Figure 1). 
The cell-binding domain of fibronectin has been the most extensively studied 
region among the many sites in extracellular matrix proteins that are known to mediate 
cell adhesion and migration (Hynes, 1990) (Pierschbacher and Ruoslahti, 1984). This 
region consists of repeating units, approximately 90 amino acid residues in length, termed 
FN type III repeats (Kornblihtt, 1985). The short polypeptide sequence RGD, which is 
located in the 10th type III repeating unit of FN, has been shown to be a key binding site 
for asJ31 integrin (Pierschbacher and Ruoslahti, 1984). But a second fragment, the 
pentapeptide PHSRN, found in the FN III domain 9 (FN 9), also contributes importantly 
to adhesion (Aota, 1994). This region has the potential to enhance overall binding to the 
integrin, and has therefore been termed as a synergy site. It bound only to the as domain 
of integrin, while ROD binds both as and PI domains. 
In 1996, Leahy, Aukhil and Erickson determined the 2.0 A crystal structure of a 
fragment of human fibronectin encompassing the seventh through the ROD-containing 
tenth type III repeats (FN 7-10). The cell-binding ROD loop is well-ordered in this 
structure and extends ~1O A away from the FN 7-10 core. The X-ray structure also 
revealed that an unusually small rotation between domains 9 and 10 creates a distinctive 
binding site, in which the ROD loop from domain 10 and the "synergy" region from 
domain 9 are on the same face of FN 7-10. Thus both binding sites are easily accessible 
to a single integrin molecule, which can explain synergistic properties of PHSRN in 
terms of the protein's structural features (Figure 2) (Leahy, 1996). 
These cell binding sites can be reproduced as biologically active short peptides, 
and when presented to cells as a peptide, a cell-binding site of fibronectin can function in 
several different ways. It can mimic the intact protein as a substrate for integrin; for 
example, a peptide could be covalently attached to a synthetic matrix and bound by a 
cell-surface integrin. The peptide analogue can also serve as a competitive inhibitor and 
thereby block adhesion and migration. Finally, binding of fibronectin peptides can 
augment integrin signaling and induce expression of collagenase or activated cell-to-cell 
adhesiveness in particular cell types (Figure 3) (Miyamoto, 1995; Yamada, 2000). This 
can be important in wound healing. 
2 
When the PHSRN was mixed with an RGD peptide, it di~ not show synergistic 
activity and it suggested that the spatial array between RGD and PHSRN in fibronectin 
could be necessary for synergistic activity (Aota, 1994). Hojo first prepared the active 
synthetic peptide containing both binding sites RGD and PHSRN and these fragments 
were linked by an amino acid/ poly(ethylene glycol) derivative (aaPEG). The PHSRN-
aaPEG-RGD hybrid strongly promoted cell spreading compared with aaPEG-RGD, 
which suggested a PHSRN synergistic effect for PHSRN in the hybrid peptide (Hojo, 
2001). 
Livant and coworkers used the naturally serum-free basement membranes and 
associated extracellular matrices of sea urchin embryos (SU-ECM) as in vitro invasion 
substrates to determine PHSRN sequence stimulating SU-ECM invasion by keratinocytes 
and fibroblasts (Livant, 2000a). They also found the wound healing effect of PHSRN 
peptide in healing-impaired and obese diabetic mice by stimulating re-epithelialization 
and contraction of dermal wounds. The arginine of this sequence appears to be crucial for 
its invasion-inducing activity because substitution of the arginine with an amino acid 
having a neural or negatively-charged side chain resulted in complete or near-complete 
loss in activity (Livant, 2000b). However, when arginine was replaced by cysteine, the 
peptide turned out to be a potent competitive inhibitor of PHSRN (Livant 2000b). The 
pentapeptide PHSCN could block both PHSRN and serum-induced invasion. Acetylated, 
amidated PHSCN (Ac-PHSCN-NH2) was 30-fold more potent. The PHSRN sequence 
induced invasion through asp I integrin by interacting with the third NH2 terminal domain 
of the as chain, which formed a pocket that may contain a divalent cation (Aota, 1994). 
In peptide sequence PHSCN, the large, electron-rich sulfhydryl group may allow the 
3 
peptide to interact tightly in the binding pocket without inducing basement membrane 
invasion. Thus, Ac-PHSCN-NH2 may be a potent antitumorigenic and antimetastatic 
agent for postsurgical use prior to extensive metastasis (Livant, 2000a). 
F or a better understanding of the role of the unusual thio-containing cysteine 
residues, and to verify whether a divalent cation presents in the fibronectin and integrin 
binding pocket, we proposed that the cysteine in peptide PHSCN can be substituted by a 
metal chelating group. Among the metal chelating possibilities, we chose the hydroxamic 
acid function to incorporate within our synthetic peptide, since hydroxamic acid has 
significant metal binding ability towards a variety of transition metal ions. Preparing 
hydroxamate variants of PHSXN peptide was chosen as an important synthesis goal in 
our study. 
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Figure 1 A model for FN9-1 0 binding to a5j31 integrin" Figure 2 Three-dimensional structure of FN9-10 
(Adapted from Redick, 2000) (Adapted from Leahy, 1996) 
Integrin 
SYllel"gy site: PHSHN 
a f3 RI445 
v. 
Key binding sitt': RGD 
Figure 3 
Peptide: 
Synthetic fibronectin peptides with different functions (adapted from: 
Yamada, 2000) 
Fl bronecti n 
PHSRN 
/1"-
(a) Mimetic (b) Competitor (c) Activator 
/' ~ ~ 
Artificial substrate PHSRN 
PHS 
I ... , 
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2 Preparation of Hydroxamic Acid 
The organic synthesis of hydroxamic acid group has been extensively explored in 
past twenty years. In general the hydroxamic acid has been synthesized by coupling 
hydroxylamine or various N- or O-alkylated derivatives with activated carboxylic acids, 
carboxylic anhydrides, acyl chlorides or esters. Water soluble coupling reagents such as 
EDC (l-(3-Dimethylaminopropyl)-3-ethyl- carbodiimide hydrochloride) and DIC 
(diisopropylcarbodiimide) are frequently used. DCC is converted to DCU and can be 
easily removed by filtration. BOP is often used for better coupling and good 
chromatographic separation of products from impurities. 
A conversion of the amino malonic acid methyl ester into the corresponding 
hydroxamic acid was achieved by directly aminolysis of the methyl ester with 
hydroxylamine, or was effected via hydrolysis of the ester to the free malonic acid under 
the treatment with hydroxylamine hydrochloride, a tertiary amine and DCC (Krumme, 
1998). Pirrung's group started from an amino acid ester and obtained an amino acid 
hydroxamate by refluxing the ester with O-benzylhydroxylamine trimethylaluminium 
reagent in toluene. The benzyl group was then removed by palladium catalyzed 
hydrogenation (Pirrung, 1995). Pd/C catalyzed hydrogenation is a routine way to 
deprotect the O-benzyl group. However, in this procedure, a mixture of the desired 
hydroxamic acid and an amide (with N-O bond cleavage) was invariably produced. 
Therefore, Mikam proposed the use of a milder catalyst Pd/BaS04 (5%) in order to obtain 
the clean hydroxamic acid product in good to excellent yield (Mikam, 1995). In another 
example, cyclo(Asu-Phe-Phe-D-Pro) was reacted with hydroxylamine, triethylamine and 
coupling reagent to generated cyclo(Asu(NHOH)-Phe-Phe-D-Pro). It is one of the first 
7 
examples of a substituted cyclic peptide with a hydroxamic acid side chain (Furumai, 
2001). The synthesis of unusual hydroxamic acids was reported by Krumme's group. A 
peptide containing an amide-bound oxalyl hydroxamic acid was. prepared from a N-
terminal free peptide, which could be converted to its oxalic acid monomethyl ester under 
basic conditions. The oxalic acid ester was then cleaved with hydroxylamine in methanol 
to obtain the desired oxalyl hydroxamic acid derivatives (Krumme, 2002). 
In recent years many research groups have started to prepare hydroxamic acids 
using solid phase reactions, which include introducing resin bound benzylhydroxylamine 
(Floyd, 1996) or binding the acetylating reagent on the resin before the coupling reaction 
(Chen and Spatola, 1997). Resin bound benzyl hydroxylamine was first introduced by 
Floyd and Whittaker and has been broadly used for C-terminal peptidic hydroxamic acid 
synthesis and for hydroxamate derivatives. Wang resin was converted to the N-
hydroxyphthalimide derivative by using a Mitsunobu reaction (Figure 4). The 0-
activated p-benzyloxybenzyl alcohol resin was treated with hydrazine in THF- ethanol to 
remove the phthalimido group, which resulted in the hydroxylamine resin. After the 
acylation, TF A was used to cleave the adduct from the resin to provide the free 
hydroxamic acid (Floyd, 1996). Following the same synthetic route, a resin with an 
ONH2 anchor was synthesized from SASRIN resin (super acid sensitive resin TM) (Figure 
5). After peptide elongation, the peptide could be cleanly cleaved from the resin under 
very mild condition (5% TFA-DCM, 15 min) to give the corresponding hydroxamic acid 
(Badaam, 1999). 
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Table 1 Preparation ofhydroxamic acids by the acylation of hydroxylamine and derivatives 
Hydroxylamine Acylating Reagent Reaction Condition Product Ref 
or derivative 
NH2OH·HCl DCC activated malonic acid Et3N in DMF Aaa-Ame(NHOBn)-Aaa' -R2 Krumme 
at 0-5 DC 1998 
NH20H· HCI Malonic acid ester CH30Na in anhydrous Aaa-Ame(NHOBn)-Aaa' -R2 Krumme 
MeOH at 5 DC 1998 
NH20H BOP, HOBt activated DMF, rt cyclo(Asu(NHOH)-Phe-Phe-D-Pro) Furumai 
\0 
cyclo(Asu-Phe-Phe-D-Pro) 2000 
i-PrNHOH EDC activated triscarboxylic THF-H20 (1:1), trishydroxamic acids Karunaratne 
acid pH 4.8, rt 1992 
Me2AICINHOR' RC02Me benzene, reflux RCONHOR' Pirrung 
1995 
NH20H Oxalic acid ester methanol Oxal hydroxamic acid derivative Krumme 
2002 
Continued Table 1 
NH2OH·HCI H MeOH, 40°C H Hu /Ny C02Me /Ny C02Me Cbz Cbz 
0, + .... (CH2)3 OH, ........ (CH2)3 1997 N N 
~ treated with H~O 
HC02H, EDC and i-Pr2Net 
lfONH2 Coupling reagent with amino Standard Fmoc HONH-Aaa-Aaa'-Aaa"-OH Floyd '--'0 ~ acids protocol 1996 







Pd(OAc)2 and PPh3 
Carboxylic acid (C-terminal DMF, rt 
G---4 '.M f-O~~~N" 
Barlaam 
PS ~-l . I Sasnn jONH2 
free peptide), EDC, DMAP 1999 
R 





DEAD, THF, OO_rt 
Hydrazine, THF-ethanol, OO_rt 
.. 
Figure 5 SASRIN resin with ONH2 anchor (Barlaam, 1999) 
OMe 
~o-{ 5 bNH2 
Hydroxamic acids could be prepared from some non-activated carbonyl 
functional groups. Whittaker's group reported a method for introducing a hydroxamic 
acid functionality via the palladium catalyzed carbonylation of aryl iodides and 
subsequent trapping of the acylpalladium (II) intermediate with a resin-bound 
hydroxylamine. Simultaneous deprotection and cleavage with TF A afforded the free 
hydroxamic acids (Grigg, 1999). The synthesis of an acyclic hydroxamic acid fragment 
can also commence with nitrone, which was treated with hydroxylamine hydrochloride 
and the product hydroxylamine was reacted with an excess of formic acid by the use of 
EDC to give an N- and O-formate moiety. Subsequent removal of the O-formate group 
afforded the hydroxamate in 71 % yield (Y okokawa, 2000). 
II 
B Research Objectives 
PHSRN represents the peptide sequence with biological importance in cell 
adhesion, cell morphology, cell migration and wound healing, and its competitive 
inhibitor, PHSCN, has significant antimetastatic and antitumorigenic activities (Livant, 
2000a). We selected twelve analogues of the PHSXX' sequence series as synthetic 
targets, some with unnatural amino acids, in order to explore their structure activity 
relationships. All analogues were prepared with their N-terminal acetylated, and C-
terminal amidated as Ac-PHSXX' -NH2• The side chains were modified at only the X and 
X' positions, but included aromatic, acidic and hydroxyl replacements for 
arginine/cysteine and for asparagines. 
As mentioned earlier, we were also interested in the role of the unusual thio-
containing cysteine residues. The SH group could be a potential metal chelator or could 
play another role. In 1994, Aota and coworkers proposed that the protein (pFn) and 
ligand (integrin) binding pocket may contain a divalent cation (Aota, 1994). If it were the 
case, PHSCN could coordinate a divalent cation, block the overall fibronectin protein 
binding to the receptor, and inhibit cell invasion. Therefore we decided to replace the 
cysteine with a chelating group to reveal whether metal binding might represent an 
important consideration for the design of second-generation compounds. 
Among the metal chelating possibilities, we chose the hydroxamic acid function 
to incorporate within our synthetic peptide, since it has significant metal binding ability 
towards a variety of transition metal ions. It is among the most widely observed chelating 
agents in natural ionophores and it has well-known pharmaceutical applications. 
Hydroxamic acids have been shown to have a role in MMP (matrix metalloproteinase) 
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inhibition, since they can serve as bidentate ligands to block MMP's at their central Zn(II) 
active site. PHSCN was reported to inhibit the expression of specific metalloproteinases 
functioning in cell migration through the extracellular matrix (Livant, 2000a). Therefore 
we aimed at preparing hydroxamate variants of PHSCN sequence and evaluating the 
angiogenesis activity of these hydroxamate peptides in order to achieve a better 
understanding of fibronectin - integrin interaction mechanism. 
C Results and Discussion 
1. Synthesis of Amino Hydroxamate Building Blocks 
In order to produce hydroxamate analogs by solid phase methods, it would be 
convenient to have appropriately protected building blocks. Accordingly we decided to 
prepare both aspartic acid and glutamic acid derived amino hydroxamates, Boc-
Asp(NHOBn)-OH and Boc-Glu(NHOBn)-OH (Figure 6). These orthogonally protected 
building blocks could be used in Boc chemistry solid phase peptide synthesis. The side 
chain O-benzyl protecting group could be resistant to 50% TF A Boc group deprotection 
and be removed by HF when the peptide is cleaved from the resin. 











Boc-Asp-OFm was the key intermediate in the synthesis of Boc-Asp(NHOBn)-
OH, following the method previously described (Spatola, 1996) (Figure 7). Boc-Asp-OH 
was converted to its anhydride by using the coupling reagent, DCC. Next the anhydride 
was esterified with 9-fluorenylmethanol and this provided a mixture of a- and p-
fluorenylmethyl esters. The desired product, a-fluorenylmethyl ester, was separated by 
recrystallization from EtOAc! hexane. O-benzylhydroxylamine was then coupled to the 
p- carbonyl group to afford Boc-Asp(NHOBn)-OFm. After base de protection of the Fm 
group, the aspartic acid hydroxamate building block Boc-Asp(NHOBn)-OH was obtained 
in 97% purity and 65% yield (from Boc-Asp-OFm). Similarly Boc-Glu(NHOBn)-OH 
was prepared from Boc-Glu-OFm in 94% purity and 71 % yield. 
Figure 7 Synthesis of Boc-Asp-OFm from Boc-Asp-OH (from Boc-Asp-OH) 
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In order to synthesize Boc-Glu-OFm, we started from the commercially available 
Boc-Glu(OBn)-OH (Figure 8). The a-carbonyl group was first protected by fluorenyl 
methyl group and the y-OBn group was removed by partial hydrogenation (3.5 h), which 
provided Boc-Glu-OFm (Romanovskis and Spatola, 1998). The Boc-Glu-OFm was then 
treated by the same method as Boc-Asp-OFm to afford Boc-Glu(NHOBn)-OH in 94% 
purity and 71 % yield (from Boc-Glu-OFm). For both Boc-Asp(NHOBn)-OFm and Boc-
Glu(NHOBn)-OFm, the fluroenyl methyl group was removed by 5% w/v piperazine in 
THF to provide the Boc protected NU-aspartyl hydroxamate and NU-glutamyl 
hydroxamate, which each has the a-carboxylic group available for further modification 
(Figure 9). 
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Figure 9 Synthesis of Boc-Asp(NHOBn)-OH and Boc-Glu(NHOBn)-OH 
CHOONH4! 10% Pdf C! MeOH 
80% 
Base Deprotection ! 30 min 
(65- 70%) 






2. Attempted Synthesis of Peptides Using a Protected Hydroxamic Acid-
Containing Amino Acid as a Preformed Building Block 
The new hydroxamate building blocks were next combined with Asn-MBHA 
resin under different reaction conditions using 1) BOP IHOBt IDIEA, 2) HBTU IDIEA or 
3) the strong coupling reagent TFFH (Carpino, 1995) as coupling reagents (Figure 10). 
However none of these reactions was successful, as monitored by the ninhydrin reaction. 
By analysis of the reaction mixture after each coupling reaction, we isolated N-OBn 
aspartimide as the glutaimide. The stable heterocycles were formed due to the side chain 
amide nitrogen, which could attack the activated carbonyl group and give the unwanted 
cyclized imide product. Once the stable five-membered aspartimide or six-membered 
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glutaimide ring on the activated carboxylic acid formed (Figure 10), the nucleophilic 
amine on the resin could no longer be coupled to the hydroxamate amino acid building 
block. Therefore, Boc-Asp(NHOBn)-OH and Boc-Glu(NHOBn)-OH were shown to be 
actively self-cyclized building blocks and were not appropriate for regular coupling 
reactions. 





X: Leu, Phe or Asn 
---------X ~ 
BOP! OlEA! OMF 











3. Solid Phase Synthesis of Side Chain Hydroxamic Acid Peptide 
Hydroxamic acid peptides were previously prepared on a solid support according 
to an effective method set up by Chen (Chen and Spatola, 1997). In this procedure a 
peptide containing an appropriately functionalized amino acid with a protected carboxylic 
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residue was assembled on the resin, prior to the side chain carboxylic group undergoing 
an N to C amidation. 
As shown in Figure 11, a residue bearing a protected carboxylic residue was 
introduced using orthogonally protected Asp/Glu derivatives. The side chain carboxylate 
group was modified by solid phase N to C amidation using an O-benzylhydroxylamine. 
The O-benzyl protection group can be removed concomitantly before or after the peptide 
resin cleavage to afford the functionalized hydroxamate side chain. 
For the synthesis of Ac-PHSX(NHOH)X'-NHz analogs, Fmoc-Glu(OtBu)-OH or 
Fmoc-Asp(otBu)-OH was incorporated onto X'-MBHA resin by coupling with protected 
O-benzyl4ydroxylamine to afford Fmoc-X(OtBu)-X'-MBHA resin. Subsequent TF A 
treatments deprotected the OtBu protecting group and the unprotected carbonyl group 
was available for further modification. BnONHz'HCI was condensed with BOP and 
DIEA, which provided Fmoc-X(NHOBn)-X'-MBHA resin and the remaining amino 
acids were coupled to the resin via routine Fmoc solid phase chemistry. After HF 
cleavage, the crude peptides were obtained. When tested with the FeCh test, the 
compounds gave the requisite pink (positive) hydroxamic acid test. Further analysis 
included proton NMR spectroscopy, which gave the characteristic pair of signals near 10 
ppm indicating an NHOH moiety, and MALDI-TOF MS which confirmed the expected 
masses. 
By following the method described above, a series of hydroxamic acid peptides 
could be synthesized. Table 2 summarizes the results from HPLC assay of the crude 
peptide and final reaction yields after purification. 
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Figure 11 Preparation of Ac-PHSE(NHOH)N-NH2 
Boc-Asn-OH 
SPPS .. Boc-Asn 
1) TFAI OCMI Anisole (501 451 5) .. FmOC-GIU(otBU)-AsnQ 
2) Fmoc-Glu(OtBu)-OH, BOP, HOBt, OlEA in OMF 
TFAI DCMI Anisole (701 251 5) 
-----------.... Fmoc-Glu-Asn 
3' 30min 
NH20Bn, BOP, HOBt, OlEA in DMF 
---------------.. Fmoc-Glu(NHOBn)-Asn 
Fmoc cycle three times "'" 
---------..... Fmoc-Pro-His(Trt)-Ser(tBu)-Glu(NHOBn)-Asn-..., 
20% Piperidine in OMF .. 
Ac-Pro-His(Trt)-Ser(tBu)-Glu(NHOBn)-Asn 




Table 2 Solid phase synthesis of side chain peptide hydroxamic acids by the following the 
hydroxamate peptide synthesis method in Figure 11 
No Peptide hydroxamic acid Peptide Content in Yield (%)b MW calcd MW found (M+ 1 t 
Crude .Qe.Qtide(% t 
1 Ac-Pro-His-Ser-Glu(NHOH)-Leu-NH2 86 78 637.7 638.7 
2 Ac-Pro-His-Ser-Glu(NHOH)-Asn-NH2 83 80 638.6 639.9 
3 Ac-Pro-His-Ser-Asp(NHOH)-Asn-NH2 54 41 624.6 625.8 
N 
0 
a Determined by RP-HPLC at A= 220 nm. b Calculated after RF-HPLC purification according to the initial substitution level 
(1.25 meq/g) on the pMBHA resin. CObtained by MALDI-TOF MS 
As shown in Table 2, the peptide Ac-Pro-His-Ser-Asp(NHOH)-Asn-NH2 was 
synthesized with much lower reaction yield than the Glu version peptide Ac-Pro-His-Ser-
Glu(NHOH)-Asn-NH2. An MALDI-MS result suggested there was a major impurity in 
the former, with a mass of 592.8 in the crude peptide. This mass was the result of 
formation a major side product. Presumably, the presence of this impurity only in the 
aspartyl case may be related to the greater stabiity of a five-membered ring (Figure 12). 
Figure 12 Side product in the preparation of Ac-Pro-His-Ser-Asp(NHOH)-Asn-NH2 
o 
....... Pro ........ 8er 
Ac""'" 'His 'N 
H 
4. Aspartimide Inhibition Study in the Synthesis of Peptide Ac-
PHSD(NHOH)N-NH2 
Aspartimide formation in classic Boc or Fmoc-solid phase synthesis of sensitive 
sequences is a serious side reaction that is difficult to both anticipate and control 
(Bodanszky, M. and Martinez, 1., 1978). Aspartimide formation could be both acid and 
base catalyzed (Figure 13, 14 and 15). The ring closure can be spontaneous, because of 
the thermodynamic stability of the five-membered aspartimide ring; the latter is 
nonetheless reactive and opens up readily under attack by nucleophiles. Strongly acidic 
conditions were required for the acidolytic cleavage of the side chain protecting group 
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and the loss of benzyl alcohol was accompanied by the formation of succinimide 
derivatives. Among the acids that catalyze the ring closure reaction, HBr in acetic acid 
and liquid HF were found to be contributory for this problem (Bodanszky, M. and 
Martinez, J., 1978). 
Figure 13 Mechanism of aspartimide formation in aspartic acid containing peptide 
H+ or base 
Figure 14 Acid catalyzed aspartimide formation 
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o 
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Base-induced aspartimide (cyclic imide) formation in Fmoc chemistry is shown in 
Figure 15. The extent of the aspartimide side-reaction is dependant upon the base 
employed for removal of the Fmoc group, and on the C-terminal residue of the aspartyl 
bond (especially prone are Gly, Ser, Thr, Asn and GIn). The ring closure reaction starts 
from the deprotonation of an NH group of a neighboring residue, followed by 
nucleophilic attack of the ~-carboxyl group to form a stable five-membered ring (Figure 
15). 
Figure 15 Base catalyzed aspartimide formation 
BH , J}0 r;;n , ," :rr\ , N ' 




Although there are no literature reports concerning the aspartimide formation 
during O-benzylhydroxamate aspartyl peptide synthesis, we believe that the aspartimide 
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formation observed in peptide 3 followed a similar mechanism as succinimide formation 
from p-benzyl aspartyl residues (Figure 16). 
Following coupling of the second ammo acid in peptides 3, synthesis was 
continued by using Fmoc chemistry, and after peptide chain elongation, anhydrous HF 
was used to cleave the peptide from the resin and remove the remaining protecting groups. 
Thus, both acid and basic catalyzed aspartimide formation needed be avoided in an 
optimized method. However, little work could be done to inhibit the acid catalysis of 
aspartimide formation in our scheme, since HF cleavage was the primary choice in 
cleaving the peptide from MBHA resin and provided the C-terminal amidated peptide. 
Thus we initiated a study involving inhibition of base catalyzed aspartimide formation. 
In the process of one N to C coupling, the p-carboxyl group of 0-
benzylhydroxamate aspartic acid could be competitively attacked by either nucleophile 
NR group including amide nitrogen of the neighboring residue or the incoming 0-
benzylhydroxylamine (Figure 16, path I). The hydroxylamine coupling provided the 
desired product, while amide N attack formed a stable five-membered aspartimide side 
product. In the meantime, the side product could also be formed from resin bound peptide. 
The deprotonated amide nitrogen would attack the aspartyl p-carbonyl group and 
NHOBn would be the leaving group in this cyclization reaction (Figure 16, path 2). 
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Figure 16 Aspartimide formation in N-C coupling (path 1) and in peptide chain 








~ 0 O~ 

















Offer and his coworkers reported that the use of N-(2-acetoxyl-4-methoxybenzyl) 
(AcHmb) aspartyl amide-bond protection is able to suppress the formation of aspartimide 
in both the initial chain assembly and during the activation and modification of the 
aspartyl ~-carboxyl group (Offer, 1996) (Figure 17). In that case, the amide nitrogen 
proton of the aspartyl bond was replaced and the sel£.cyclization could not proceed. 
25 
Figure 17 Backbone protecting group Hmb 
O-COCH3 
o CH 0 








Another application involving peptide synthesis on a base-labile functionalized 
resin was carried out in Rabanal' s group and great success was achieved by using the 
bifunctional linker N-[9-hydroxylmethyl]-2-fluorenyl] succinamic acid (HMFS) handle 
on PEGA-resin (Figure 18). They synthesized the peptide containing an -Asp-Ala-
sequence on a HMFS-PEGA-resin using Boc/Bn chemistry and cleaved the peptide from 
resin with a mild base, morpholine (Rabanal, 2000). This strategy effectively eliminated 
the aspartimide formation by avoiding strong acid (HF cleavage) or strong base 
(piperidine deprotection). 
In another approach a new protecting group for aspartic acid was synthesized and 
applied in both Fmoc and Boc solid phase peptide synthesis with minimal aspartimide 
formation. The protecting group, p-3-methylpent-3-yl (Mpe) ester, has good flexibility 
and large steric hindrance and can interfere with the attack of the amide bond nitrogen on 
the p-carbonyl group and lor the abstraction of the NH proton at the amide bond 








HMFS handle -Asp(OMpe )-OH 
Among these reported methods to inhibit base catalyzed aspartimide formation, 
most of them employ novel aspartic acid side chain protecting groups or backbone 
protecting groups (Karl strom, 1996; Karlstrom, 1995; Rabanal, 2000) and none of these 
could provide an efficient solution for our problem. Therefore we combined several 
strategies in optimization of the chemistry of Figure 11 to improve the overall yield of 
our hydroxamated aspartic acid peptide. First we introduced a neighboring residue with a 
bulky side chain; that is, we used Boc-Asn(Xan)-OH to replace the unprotected Boc-Asn-
OH (Figure 19). Usually asparagine can be used in either Boc or Fmoc chemistry without 
a side chain protecting group. In our study the bulky 9-xanthenyl (Xan) group was 
introduced as a side chain protecting group to increase the steric hindrance toward 
asparagines NU deprotonation and consequently impede the intramolecular ring closure 
process. 
Base induced aspartimide formation could also be inhibited by the use of 
piperazine in Na-Fmoc deprotection according to a report from Wade (Wade, 2000). The 
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effect of extended treatment of piperazine as reagent on two sensitive peptide sequences 
was examined and piperazine caused less side reactions comparing to other bases, 
including piperidine, I-hydroxypiperidine, tetrabutylammonium fluoride, or 1,8-
diazabicyclo[5.4.0]undec-7-ene (Wade, 2000). Therefore, 6%w/v piperazine in DMF was 
used to replace 25% piperidine in DMF for Fmoc deprotection in our later hydroxamate 
peptide syntheses. 
As mentioned before, in the process of N-C coupling our activated carbonyl 
group could be competitively attacked by nucleophiles, either NHOBn or the neighboring 
backbone NH. However, the NHOBn was protonated after TF A treatment of the peptide 
and the coupling step could be slowed down. NHOBn would lose its edge in the 
competition and this would result in aspartimide formation. It has been reported that an 
extra neutralizing step would eliminate the effect of residual acid (TF A) in aspartimide 
formation (Chen and Spatola, 1997). 






Overall four modifications were made to the optimized method (Figure 20) 
compared to the original method (Figure 11). Boc-Asn-OH was replaced by Boc-
Asn(Xan)-OH, 6% w/v piperazine was used in Fmoc deprotection, and the resin was 
neutralized by 10% DIEA before N-C coupling. Most importantly the side chain 
modification was introduced after the peptide chain was elongated, in order to minimize 
the exposure of the NHOBn group to piperazine and eliminate the aspartimide formation 
observed in Figure 16 path 2. These changes lead to obvious improvement in the 
synthesis of Ac-Pro-His-Ser-Asp(NHOH)-Asn-NH2, since the yield was increased from 
41 % to 68% and the formation of succimide was effectively inhibited. 
Figure 20 Modified methodology to prepare Ac-PHSD(NHOH)N-NH2 
spps 
Boc-Asn(Xan)-OH + Boc-Asn(Xan) 
1) TF AI OeMI Anisole (50/4515) 
• FmOC-ASp(otBU)-ASn(Xan)Q 
2) Fmoc-Asp(O!Bu)-OH, BOP, HOBt, OIEA in OMF 
1) 6% w/v piperazine in OMF 
Fmoc-Pro-His(Trt)-Ser(tBu)-Asp(otBu)-Asn(Xan) 
Fmoc cycle four times 
I) 6% w!v piperazine in OMF 
2) Acetic Anhydride, OlEA in OeM Ac-Pro-His(Trt)-Ser(tBu)-Asp(otBu)-Asn(Xan) 
1) TF AI OeM! Anisole (70/251 5), 3 X 30min 
2) 10% OIEA in OMF 
--------------.. Ac-Pro-His-Ser-Asp(NHOBn)-Asn (Xan) 




5. Parallel Synthesis of Ac-PHSXX'-NH2 Peptides 
Analogues of parent peptides PHSRN and PHSCN were prepared to explore the 
role of several of the amino acids in peptide's cell invasion inducing activity. As 
mentioned before, hydroxamate derivatives of PHSXX' peptide were prepared because of 
the high metal binding ability of hydroxamic acids and the activity of hydroxamate 
peptides would indicate if the metal binding is involved in the anti-invasion-inducing 
activity. Peptide PHSDN, the precursor of PHSD(NHOH)N, was also included in these 
analogues. In the meantime, cysteine was replaced by a similar sized amino acid, serine, 
which has a hydroxyl side chain, and unlike the thiol group, does not have metal binding 
ability. 
The importance of the C-terminal asparagine was examined by substituting it with 
Phe and Tyr. Both Phe and Tyr are hydrophobic aromatic amino acids comparing to Asn, 
which is slightly hydrophilic with an amide side chain. Since Phe and Tyr have obviously 
larger steric factors than Asn (steric factor: Asn: 117.7 A, Phe 189.9 A and Tyr: 193.6 A), 
we could derive the information about whether the neighboring side chain of the metal 
binding group involved interference in its access to the divalent cation pocket and finally 
affected the activity of PHSXX' peptides. 
Analogues for PHSRN (agonist to cell adhesion): PHSRF, PHSRY 
Analogues for PHSCN (antagonist to cell adhesion): PHSCF, PHSCY. 
Peptides shown in Table 3 were prepared parallely in the fritted syringes, which 
were set up on the drain and wash block. Dried MBHA resin was loaded and swollen in 
syringes. Each peptide was synthesized by a series of Boc cycles on the MBHA resin, 
and was cleaved by HF simultaneously after peptide chain elongation. The peptides were 
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purified by C-18 column chromatography under water! acetonitrile stepwise elution. The 
identity of the peptide was confirmed by MALDI-TOF mass spectroscopy, which showed 
the presence of the pseudomolecular ion [m + Ht. 
6. Biological Activity Tests of Peptide Analogues Ac-PHSXX'N-NH2 
Peptide analogues (1-6 and 8-12) were tested in an ex vivo ring angiogenesis 
assay and the results were summarized in Table 4. First, aortic arches were removed from 
chicken eggs at day 14 of embryonic development and individual peptide was applied to 
small pieces of aortic rings. The aortic ring sprouting was detected and the change of the 
diameter of the aortic ring was recorded at 24 hand 48 h, respectively. Most of the 
peptides were tested once, some of them were tested twice and some experimental results 
were not reproducible. In some cases, the inconsistent nature of the assay results made it 
impossible for us to make any definitive conclusion about the biological activity of these 
peptides. The hydroxamate peptide Ac-PHSE(NHOH)N-NH2 was shown to be inhibitory, 
Ac-PHSD(NHOH)N-NH2 and Ac-PHSE(NHOH)L-NH2 were inactive. Whether the 
metal binding group was involved in cell inductive invasion activity as its effect on 
angiogenesis activity will require further verification, perhaps using a more robust assay 
procedure. 
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Table 3 Summary of Ac-PHSXX' -NH2 peptides analogues in solid phase peptide synthesis Boc chemistry 
(peptides 7-12 were prepared by parallel peptide synthesis) 
Peptide content in 
Yield MW+l 
No Peptide 
crude peptide (% t MWcald (%)b foundc 
4 Ac-PHSRN-NH2 94 89 650.3 651.4 
5 Ac-PHSCN-NH2 82 77 597.4 598.4 
6 Ac-PHSSN-NH2 93 56 581.5 582.7 
w 
tv 7 Ac-PHSDN-NH2 78 69 609.7 610.6 
8 Ac-PHSDF-NH2 80 73 642.7 643.8 
9 Ac-PHSCF-NH2 78 72 630.8 631.8 
10 Ac-PHSRF-NH2 85 82 683.8 684.8 
11 Ac-PHSCY-NH2 78 70 646.8 647.7 
12 Ac-PHSRY-NH_2 _ 93 87 699.7 700.9 
a Determined by RP-HPLC at A=220nm. bCalculated after RP-HPLC purification according to the initial substitution level (1.25 meq/g) 
on the pMBHA resin. C Obtained by MALDI-TOF MS 
w 
w 
Table 4 Ac-PHSXX' -NH2 peptides ex vivo ring angiogenesis assay, 200 ~g/ mL at 24 h and 48h 
Average aorta diameter (em) 
Peptide 
Experiment I Experiment II Experiment III 
24h 48h Conclusiona 48 h Conclusionb 48hr Conclusionc 
Ac-PHSRN-NHz 0 0 Inhibitory 
Ac-PHSRF-NHz 0.47 1.22 Active++ 0.75 Inactive 
Ac-PHSRY-NHz 0.08 0.53 Inactive 
Ac-PHSCF-NHz 0.72 1.41 Active+++ 
Ac-PHSCY -NH2 0.34 0.91 Active+ 1.42 Active+ 
Ac-PHSCN-NHz 0.07 Inhibitory 
Ac-PHSSN-NH2 0.52 1.02 Active+ 0.84 Inactive 
Ac-PHSDF-NHz 0.23 0.82 Inactive 1.51 Active+ 
Ac-PHSE(NHOH)N-NHz 0 0 Inhibitory 
Ac-PHSD(NHOH)N-NHz 
Ac-PHSE(NHOH)L-NHz 0.12 0.54 Inactive 0.93 Inactive 
The data was provided by Hynda K. Kleinman. 
Conclusion was drawn by comparing the data with a: negative control values: 0.42 cm (24 h reading)md 0.70 cm (48 h reading) and positive control 
values: 2.03 cm (24 h reading) and 3.71 cm (48 h reading); b: negative control value: 0.81 cm (48 h reading) and positive control value: 2.70 cm (48 h 
reading); c: negative control value: 0.86 cm (48 h readi~) and positive control value: 2.80 cm (48 h reading). 
D. Conclusion 
In our study two new hydroxamate aspartic acid and glutamic acid building 
blocks were synthesized with high purity and good yield. The failure of these NU _ 
protected amino acids in coupling reactions was due to an intramolecular cyclization 
giving succinimide formation. Therefore the hydroxamate peptides were prepared 
indirectly using solid phase hydroxamate peptide synthesis method {Chen and Spatola, 
1997). The side chain carboxyl group of a peptide synthesized on para-
methylbenzhydrylamine (pMBHA) resin was converted to a hydroxamate functional 
group by condensing with NH20Bn, and the OBn group was removed during HF 
cleavage of the peptide resin. Severe aspartimide formation was observed in the synthesis 
of Ac-PHSD(NHOH)N-NH2, and several modifications were made to the original 
hydroxamate peptide synthesis. Neighboring asparagine was introduced with bulky side 
chain protecting group; piperidine was replaced with piperazine to remove }f-Fmoc 
group; side chain modification was made after peptide chain elongation and the resin was 
neutralized before N-C coupling and the aspartimide formation was inhibited effectively 
with the optimized method. All Ac-PHSXX' -NH2 analogues were prepared by solid 
phase peptide synthesis method and examined by a ring angiogenesis assay by Dr. 
Kleiman at the institute NIH. Hydroxamate analogue Ac-PHSE(NHOH)N-NH2 showed 
the expected angiogenesis inhibition activity, however, peptide Ac-PHSD(NHOH)N-NH2 
which is one CH2 short on the hydroxamate amino acid side chain turned out to be 
inactive. Therefore, whether hydroxamate group affected the ring sprouting activity could 
not be determined in these experiments and whether peptide binding the divalent pocket 
to influence cell invasion need be tested further. Peptides with an aromatic amino acid at 
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position 5 were found to be active with Ac-PHSCY-NH2 providing approximately as 
active as Ac-PHSRF-NH2. 
E. Experimental Section 
Instruments and materials 
The analytical reversed phase-high performance liquid chromatography (RP-
HPLC) was performed on a Vydac 218TP54 CI8 column (4.6 x 250 mm) on a Hitachi 
655A system equipped with an L-5000 controller and D-2000 integrator. Peptides were 
eluted with the following gradient system: 5-90% CH3CN/ water with a constant 
concentration of TF A (0.05% v/v) in 30 min, flow 1.0 mLimin and the separation was 
monitored by UV detector set at 220 nm. HF cleavage of peptides from resin was carried 
out in a Kel-F HF apparatus (Peptide Institute, Osaka). The molecular weight of the 
peptide was verified by MALDI-TOF MS and all the calculated molecular weights 
represent the exact molecular weight in this chapter. TLC was performed on Merck 254 
plates using the following solvent system: 
A: n-BuOH: H20: AcOH, 4:1:1 
B: EtOH: Hexane 1:1 
C: CHCb: EtOH: AcOH 85:10:5 
The pMBHA resin (1.2 meq/g) was a gift from Peptides International (Louisville). 
BOP coupling reagent was purchased from Advanced Chern Tech (Louisville). All other 
reagents were reagent grade and were used without further purification. 
1. Preparation of Boc-Asp(NHOBn)-OFm and Boc-Glu(NHOBn)-OFm 
(1) Preparation of Boc-Asp-OH, NU_ (t-butyloxycarbonyl) aspartic acid (13) 
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L-Aspartic acid (10 g, 75.1 mmol) and sodium hydroxide (6 g, ISO mmol) were 
dissolved in dioxane-water (1: I) solution (60 mL). The solution was chilled with an ice 
bath for IS min. Boc anhydride (21 g, 96.2 mmol) in IS mL dioxane was added to the 
aspartic acid solution dropwise while stirring and the solution temperature was controlled 
under O°c. After the addition of (Boc )20, the ice bath was removed and the reaction 
stirred at ambient temperature for 72 hours. During the reaction process, sodium 
hydroxide (6 g, ISO mmol) was added to maintain the pH above 10. The dioxane was 
removed by evaporation. The remaining aqueous solution was washed with diethyl ether 
(2 x 50 mL) and adjusted to pH 2 by 4N HCI aqueous solution. Ethyl acetate (4 x 70 mL) 
was used to extract Boc-Asp-OH. The organic layers were combined and washed with 
water (2 x 40 mL) and saturated brine solution (2 x 40 mL), then dried by MgS04. The 
solvent was evaporated and the product was recrystallized from ethyl acetate-hexane. 
Yield: 16 g (98%) 
Rf: 0.7 (solvent A) 
m.p.: liS-117°C 
IH-NMR (CDCh) D ppm: 1.43 (s, 9H); 2.84 (dd, IH), 3.10 (dd, IH); 4.61 (m, IH); 
5.67 (dd, IH) 
(2) Preparation of Boc-Aspartic Acid Anhydride (14) 
DCC (14.6 g, 70.8 mmol) was dissolved in 20 mL ethyl acetate and added 
portionwise to a stirred solution of Boc-Asp-OH (15 g, 64.4 mmol) in ethyl acetate (40 
mL) at O°C. The reaction mixture was stirred in ice bath for I hr and then at ambient 
temperature for another hour. DCU precipitated from the reaction was filtered and the 
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solvent evaporated to dryness. Boc-aspartic acid anhydride (14.5 g) was obtained and 
directly used in the next step of reaction. 
(3) Preparation of Boc-Asp-OFm, f'tf'- (t-butyloxycarbonyl) aspartic a-
fluorenylmethyl ester (15) 
Boc-aspartic acid anhydride (14.5 g) was dissolved in anhydrous THF (45 mL). 9-
fluorenylmethanol (12.6 g, 64.4 mmol) and DIEA (10.9 mL, 64.4 mmol) were added to 
the reaction solution respectively and the reaction was stirred overnight. The solvent was 
removed by evaporation and the remaining oily product was dissolved by 40 mL EtOAc. 
The organic phase was washed by IN HCI (3 x 30 mL), NaHC03 (3 x 30 mL), water (3 x 
30 mL) and brine (3 x 30 mL). Finally the EtOAc solution was dried over MgS04• The 
product contained both a and P isomers and the desired a-fluorenylmethyl ester was the 
predominant in mixture (67%: 33%) and was obtained by recrystallization from the 
solvent of EtOAc : hexane (2: I). 
Yield: 12 g (47% from L-aspartic acid) 
Rf: 0.4 (solvent B) 
m.p.: 163-164 °C 
IH-NMR (CD3CN) 8 ppm 1.46 (s, 9H); 2.74 (m, 2H); 4.28 (m, IH); 4.43-4.47 (m, 
2H); 4.58 (m, IH); 5.82 (dd, IH); 7.36-7.88 (m, 8H) 
(4) Preparation of Boc-Glu(OBn)-OFm, f'tf' - (t-butyloxycarbonyl) glutamic a-
fluorenylmethyl, g-benzyl ester (16) 
The synthesis started from NU _ (t-butyloxycarbonyl)-g-(benzyl ester)-L-glutamic 
acid. Boc-Glu(OBn)-OH (6 g, 18 mmol), fluorenylmethanol (3.9 g, 20 mmol) were 
dissolved in 50 mL EtOAc with 1.46 mL (18 mmol) pyridine. Boc-anhydride (4.7 g, 21.6 
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mmol) in EtOAc was added to the mixture and allowed to react for 40 h. Boc-anhydride 
(1.9 g, 8.7 mmol) was introduced to the reaction mixture after 20 h to process the reaction 
completely. The reaction was monitored by TLC and stopped when the starting material 
spot disappeared on TLC plate. Working up involved washing the mixture by 5% 
NaHC03 (3 x 30 mL), water (2 x 20 mL), 10% KHS04 (2 x 20 mL) and NaCI (20 mL) 
and drying over the NaS04. After removing the organic solvent by evaporation, the 
product was crystallized in 20 mL methanol. The sample was obtained as white solid in 
7.S g and the yield was 81.3%. 
Rf: 0.8 (solvent C) 
m.p.: 96-97 °C 
IH-NMR (DMSO-d6) 8 ppm: 1.34 (s, 9H); 1.68-1.82 (m, 2H), 2.28-2.36 (m, 2H), 
4.02-4.43 (m, 4H), 5.06 (s, 2H), 7.23-7.88 (m, 14H) 
(5) Preparation of Boc-Glu-OFm, ff1- (t-butyloxycarbonyl) glutamic a-
fluorenylmethyl ester (17) 
Boc-Glu(OBn)-OFm (6.6 g, 12.8 mmol) was dissolved in 75 mL methanol, water 
and acetic acid (6: 1: 1) solvent. 20 mg 10% Pd/C was added in the mixture. The reaction 
flask was flushed by nitrogen for three minutes before introducing hydrogen. Boc-
Glu(OBn)-OFm was hydrogenated for three hours until the TLC analysis showed 
completion of the reaction. After the catalyst was filtered off and the filtrate was 
evaporated, the oily product was crystallized by hexane. After washing the crystallized 
product by hexane (3 x 10 mL), 3.8 gpure product was obtained. Yield: 70% 
Rf: 0.5 (solvent C) 
mp: 95-97 °C 
38 
1H-NMR (DMSO-d6) 8 ppm: 1.34 (s, 9H); 1.68-1.88 (m, 2H), 2.28-2.56 (m, 2H), 
4.12-4.88 (m, 4H), 7.29-7.88 (m, 9H), 12.0 (s, 1H) 
(6) Preparation of Boc-Asp(NHOBn)-OFm, }f-- (t-butyloxycarbonyl) aspartic 
a-fluorenylmethyl, p-O-benzyl hydroxamate ester (18) 
Boc-Asp-OFm (14.6 mmol, 6 g) and BOP (14.6 mmol, 2.33 g) were dissolved in 
50 mL dichloromethane. O-benzylhydroxylamine hydrogen chloride (14.6 mmol, 2.33 g) 
was added to the mixture as the solid, which was dissolved after introducing DIEA (29.2 
mmol, 5.07 mL). The reaction was then maintained at room temperature for 9 h. The 
solvent was evaporated and EtOAc (30 mL) was added to the remaining oil. The organic 
solution was washed by IN HCI (3 x 20 mL), saturated NaHC03 (3 x 20 mL), water (3 x 
20 mL) and brine (3 x 20 mL). The organic layer was dried by MgS04 and after 
removing the EtOAc, the sample was crystallized in 10 mL hexane. The desired product 
was obtained in 6.3 g (yield: 90%). 
Rf: 0.7 (solvent B) 
m.p.: 107-109 °C 
IH-NMR (CD3CN) 8 ppm: 1.46 (s, 9H); 2.56 (m, 2H); 4.28 (m, 1H); 4.43-4.47 
(m, 2H); 4.58 (m, 1H); 4.82 (s, 2H), 5.84 (b, 1H); 7.36-7.88 (m, 13H); 9.36 (s, 1H) 
(7) Preparation of Boc-Glu(NHOBn)-OFm, }? - (t-butyloxycarbonyl) 
glutamic a-fluorenylmethyl, g-O-benzyl hydroxamate ester (19) 
Boc-Glu-OFm (4.7 mmol, 2 g) and BOP (4.7 mmol, 2.1 g) were dissolved in 20 
mL DCM. O-benzylhydroxyl amine hydrogen chloride (4.7 mmol, 0.57 g) was added to 
the mixture as solid, which was dissolved after introducing DIEA (9.4 mmol, 1.62 mL) 
and the reaction mixture was stirred for 6 hr in room temperature. The solvent was 
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evaporated and the oily product was dissolved by 15 mL EtOAc and the organic layer 
was washed by 3 x 10 mL IN HCI, 3 x 10 mL saturated NaHC03, 3 x 10 mL water and 3 
x 10 mL brine. The organic solution was dried with Na2S04 and after removing the 
EtOAc, the sample was crystallized in 10 mL hexane. The expected product was obtained 
in 2.3 g with the yield was 92%. 
Rf: 0.7 (solvent B) 
m.p.: 95-97 °C 
IH-NMR (CD3CN) 8 ppm: 1.46 (s, 9H); 1.72 (m, IH), 1.83 (m, IH), 2.05 (m, 2H); 
3.88 (m, IH); 4.44 (m, 2H); 4.54 (m, IH); 4.81 (s, 2H), 5.84 (dd, IH); 7.36-7.88 
(m, 13H); 9.36 (s, IH) 
2. Preparation of Boc-Asp(NHOBn)-OH and Boc-Glu(NHOBn)-OH 
(l) Preparation of Boc-Asp(NHOBn)-OH, /If" - (t-butyloxycarbonyl) aspartic 
p-O-benzyl hydroxamate ester (20) 
Boc-Asp(NHOBn)-OFm (2.1 g, 4.1 mmol) was dissolved in 30 mL 25%(v/v) 
piperidine in THF and allowed to react for 35 min in room temperature. After THF 
removing, the remaining oil drop was dissolved by 25 mL saturated NaHC03 solution. 
The aqueous layer was washed with 20 mL EtOAc for three times before adjusted to pH 
2 by IN HCI acidification. The product was extracted from the water layer by 3 x 30 mL 
EtOAc and dried over MgS04. The organic solvent was evaporated and 700 mg greasy 
product was obtained. The yield was 51 %. 
Rf: 0.6 (solvent B) 
mp: 70-72°C 
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lH-NMR (DMSO-d6) i5 ppm: 1.40 (s, 9H); 2.30 (m, lH); 2.42 (m, lH); 4.32 (m, 
IH); 4.79 (s, 2H); 6.98 (b, IH); 7.38 (m, 5H); 11.02 (s, IH) 
• 
(2) Preparation of Boc-Glu(NHOBn)-OH, ]1/"- (t-butyloxycarbonyl) glutamic 
g-O-benzyl hydroxamate ester (21) 
Boc-Glu(NHOBn)-OFm (3 g, 5.7 mmol) was dissolved in 30 mL 5% (w/v) 
piperazine in THF and allowed to react for 30 min. THF was evaporated, and the 
remaining oil drop was dissolved by 20 mL saturated NaHC03 solution. The NaHC03 
layer was washed with 15 mL EtOAc for three times and acidified to pH 2 with IN HCl. 
The product was extracted from the water layer by washing with 3 x 20 mL EtOAc and 
dried over MgS04. The organic solvent was evaporated and 1.3 g product was obtained. 
The yield was 65%. 
Rf: 0.6 (solvent B) 
IH-NMR (DMSO-d6) i5 ppm: 1.38 (s, 9H); 1.64 (m, IH); 1.88 (m, IH); 3.82 (m, 
IH); 4.78 (s, 2H); 7.01 (b, IH); 7.40 (m, 5H); 11.02 (s, IH) 
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Table 5 Solid Phase Peptide Synthesis Protocol 
Boc Chemistry Fmoc Chemistry 
Step Time Time 
Reagent Reagent 
(min) (min) 
TF AlDCMlanisole Piperidine/DMF 
Deprotection 30 30 
(50/45/5, v/v/v/%) (1/4, v/v/%) 
DCM 3 x I DMF 3 x I 
Wash Methanol 2 x I Methanol 2 x I 
DMF 3 x 1 DMF 3 x 1 
Kaiser Test Kaiser test reagents 5** Kaiser test reagents 5** 
Boc-A.A (3 eq) Fmoc-A.A (3 eq) 
Coupling Coupling Reagent (3 eq) 60 Coupling Reagent (3 eq) 60 
mEA (6 eq) mEA (6 eq) 
DMF 3 x I DMF 3 x 1 
Wash Methanol 2 x I Methanol 2 x I 
DCM 3 x 1 DMF 3 x I 
Kaiser Test Kaiser test reagents 5*** Kaiser test reagents* 5*** 
*Kaiser test reagents: 
1 2 mL 0.01 MKCN 100 mL pyridine 
2 500 mg ninhydrin in 10 mL n-BuOH 
3 80 g phenol in 20 mL n-BuOH 
Removed a few milligrams of the peptide-resin with a spatula to a test tube and 
added 2-3 drops of Kaiser test reagents 1, 2 and 3. Placed the tube in 100°C water bath 
for five minutes. 
**Positive result (resin beads tum blue or brown (in the case of proline)), do next 
coupling. Negative result (resin beads remain white), repeat the deprotection. 
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***Negative result (resin beads remain white or yellow), go to next cycle. Positive result 
(resin beads tum blue or brown (in the case of proline)), repeat the coupling. 
3 Preparation of Ac-PHSXX'-NH2 sequences 
(1) Preparation of Ac-Pro-His-Ser-Arg-Asn-NH2 
(i) Preparation ofH-Pro-His-Ser-Arg-Asn-MBHA resin (22) 
Peptide synthesis started from the C-terminal amino acid being loaded on the 
polystyrene resin. The reaction was processed in the 80 mL reaction vessel, which was 
equipped with a frit on both ends. MBHA resin (4 g, 4.8 mmol, substitution = 1.2 meq/g) 
was swelled in DIEAlDMF (1 : 9) solvent overnight. DMF solvent was filtered out. Boc-
Asn-OH (3.34 g, 14.4 mmol), BOP (6.37 g, 14.4 mmol) and HOBt (1.95 g, 14.4 mmol) 
were dissolved in 30 mL anhydrous DMF with 5 mL, 28.8 mmol DIEA. The mixture was 
poured into the reaction vessel and allowed to react for one hour. Afterwards, the 
unreacted amino acids and coupling reagents were filtered out with DMF solvent. The 
resin was washed with 3 x 20 mL DMF, 2 x 20 mL methanol and 3 x 20 mL DCM. After 
a Kaiser test, the color of resin remained yellow, which showed the first amino acid was 
coupled to the resin completely. Mixed solvent TFAlDCM/anisol (45/50/5) (30 mL) was 
used to remove the Na-Boc group. After 30 min, the solvent was filtered out, and the 
resin was washed with 3 x 20 mL DCM, 2 x 20 mL methanol and 3 x 20 mL DCM. Once 
again the Kaiser test was applied and the light yellow resin turned to dark blue color. So 
the Boc group was removed successfully and the resin was ready for next protected 
amino acid coupling. 
By repeating the coupling and deprotection cycle according to the protocol in 
Table 5, reagents including Boc-Arg(Tos)-OH (6.14 g, 14.4 mmol), Boc-Ser(Bn)-OH 
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(4.24 g, 14.4 mmol), Boc-His(Tos)-OH (5.88 g, 14.4 mmol) and Boc-Pro-OH (3.09 g, 
14.4 mmol) were introduced to the resin one by one. 
(ii) Preparation of Ac-Pro-His-Ser-Arg-Asn-MBHA resin (23) 
The N-terminal resin (22) was acetylated by shaking with 2.26 mL (24 mmol) 
acetic anhydride in 30 mL DCM overnight. Finally the resin was filtered, and washed 
with CH2Cl2 (3x), MeOH (2x) and CH2Clz (3x) and dried in vacuo. 
(iii) Preparation of Ac-Pro-His-Ser-Arg-Asn-NH2 (4) 
The dry peptide resin (23) was placed into the HF reaction vessel with 0.5 mL of 
anisole. The reaction vessel was hooked to HF apparatus and cooled in a dry ice/acetone 
bath for twenty minutes. The reaction vessel was evacuated and ready to collect HF 
liquid. Hydrogen fluoride (20 mL) was then condensed into the vessel and the reaction 
was allowed to proceed with stirring under an ice bath. After one hour reaction, HF was 
evaporated and the scavengers were extracted by washing with ethyl ether 30 mL for 
three times. The peptide was then extracted from the resin by 25% acetic acid and the 
acetic acid extract was lyophilized to provide the product as white powder (Yield: 2.78 g, 
89%). 
RP-HPLC Rt (min): 5.07 
MALDI-MS: calc. (C26H42N120S) 650.3, found (M+H): 651.6 
(2) Preparation of Ac-Pro-His-Ser-Cys-Asn-NH2 (5) 
MBHA resin (2 g, 2.4 mmol, substitution= 1.2 meq/g) was swelled in DIEAlDMF: 
119 for 30min. Boc-Asn(Xan)-OH (3.96 g, 9.6 mmol), Boc-Cys(PMB)-OH (3.28 g, 9.6 
mmol), Boc-Ser(Bn)-OH (2.83 g, 9.6 mmol), Boc-His(Tos)-OH (3.93 g, 9.6 mmol) and 
Boc-Pro-OH (2.06 g, 9.6 mmol) were coupled to the resin by following the classic Boc 
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cycles. The coupling reagent in each cycle included BOP (4.25 g, 9.6 mmol), HOBt (1.30 
g, 9.6 mmol) and DIEA (3.37 mL, 19.2 mmol). After HF cleavage, acetic acid extraction 
and lyophilize, peptide was obtained as white solid in 1.1 g (Yield 77%). 
RP-HPLC Rt (min): 10.54 
MALDI-MS: calc. (C23H3SN90gS) 597.2, found (M+H): 598.5 
(a) Preparation of Boc-His(Tos)-OH (24) 
Boc-His(Tos)-OH . DCHA (2.2 g, 3.72 mmol) was suspended in 15 mL EtOAc. 
After IN ice cold H2S04 (2.3 mL, 4.46 mmol) was added to the solution, the suspended 
amino acid was dissolved. The EtOAc layer was removed after being shaked with 
aqueous phase in the separatory funnel. The remained aqueous phase was washed with 20 
mL EtOAC twice. All the organic solution wash combined and washed with 20 mL water 
for two times and dried under Na2S04. The organic phase was evaporated to provide 
white solid in 1.46 g. (Yield: 96%). 
(3) Preparation of Ac-Pro-His-Ser-Ser-Asn-NH2 (6) 
MBHA resin (1 g, 1.2 mmol, substitution= 1.2 meq/g) was swelled in 
DIEA/DCM: 1/9 overnight. The Boc-Asn-OH (0.84 g, 3.6 mmol), Boc-Ser(Bn)-OH (1.06 
g, 3.6 mmol), Boc-Ser(Bn)-OH (1.06 g, 3.6 mmol), Boc-His(Tos)-OH (1.46 g, 3.6 mmol) 
which was recovered from Boc-His(Tos)-OH . DCHA, and Boc-Pro-OH (1.21 g, 3.6 
mmol) were coupled to the resin by following the classic Boc cycles. BOP (1.59 g, 3.6 
mmol), HOBt (0.48g, 3.6 mmol) and DIEA (1.25 mL, 7.2 mmol) were used as coupling 
reagents in each cycle. After HF cleavage, white flake was obtained in 380 mg (Yield: 
55%). 
RP-HPLC Rt (min): 18.27 
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MALDI-MS: calc. (C22H34NgOgS) 581.3, found (M+H): 582.7 
(4) Parallel synthesis: Ac-Pro-His-Ser-Asp-Asn-NH2 (7), Ac-Pro-His-Ser-
Asp-Phe-NH2 (8), Ac-Pro-His-Ser-Arg-Phe-NH2 (10), Ac-Pro-His-Ser-Arg-Try-
NH2 (12), Ac-Pro-His-Ser-Cys-Phe-NH2 (9) and Ac-Pro-His-Ser-Cys-Tyr-NH2 
(11). 
The protected amino acids used in the parallel peptide synthesis including: Boc-
Asn-OH (Chem-Impex), Boc-Phe-OH (Chem-Impex), Boc-Tyr(2,6-diCl-Bn)-OH 
(Bachem), Boc-Asp(OBn)-OH (Peninsular), Boc-Cys(Pmb)-OH (Bacham), Boc-
Arg(Tos)-OH (Bacham), Boc-Ser(Bn)-OH (Chem-Impex), Boc-His(Tos)-OH (recovered 
from Boc-His(Tos)-OH . DCHA which was purchased from Bacham) and Boc-Pro-OH 
(Bacham). 
Dry MBHA resin (150 mg, 0.18 mmol) was weighed into six fitted syringes 
separately and the resin was swell in 6 mL 10% DIEAI DMF overnight. The amino acids 
were coupled to the resin by classic Boc chemistry. The amount and the adding sequence 
of Boc amino acids are summarized in Table 6. Each amino acid was dissolved in the 
DMF (6 mL) with BOP (238.9 mg, 0.54 mmol), HOBt (72.9 mg, 0.54 mmol) and DIEA 
(0.19 mL, 1.08 mmol) before added to the resin. After completion of the chain building, 
the peptides were acetylated with 1.0 mL, 5.4 mmol acetic anhydride in DMF. 
The cleavages were achieved in the 24 chamber multiple HF apparatus. For each 
syringe, the resin was placed in a cleavage vessel with 0.5 mL anisole and 5 mL HF. The 
mixture was stirred at 0 °C for two hours before the HF was removed. The peptides were 
extracted with 30 mL 25% acetic acid and lyophilized to provide white to light yellow 
solid. Yield: 70% - 89%. 
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Ac-PHSDN-NH2: RP-HPLC Rt (min): 10.56 
MALDI-MS: calc. (C24H3SN901O) 609.3, found (M+H), 610.6 
Ac-PHSDF-NH2: RP-HPLC Rt (min): 12.77 
MALDI-MS: calc. (C29H3SNS09) 642.3, found (M+H), 643.8 
Ac-PHSCF-NH2: RP-HPLC R t (min): 13.84 
MALDI-MS: calc. (C2sH3SNs07S) 630.3, found (M+H), 631.8 
Ac-PHSRF-NH2: RP-HPLC Rt (min): 12.22 
MALDI-MS: calc. (C3IH4SNII07) 683.4, found (M+H), 684.8 
Ac-PHSCY-NH2: RP-HPLC Rt (min): 12.52 
MALDI-MS: calc. (C2sH3gNgOgS) 646.3, found (M+H), 647.7 
Ac-PHSRY-NH2: RP-HPLC Rt (min): 11.19 
MALDI-MS: calc. (C31~sNIIOg) 699.4, found (M+H) , 700.9 
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Table 6 Boc-amino acid building block used in parallel synthesis peptide 7,8,9,10, 11 and 12 
Syringe 1: Ac-PHSDN-NH2, Syringe 2: Ao-PHSDF-NH2, Syringe 3: Ao-PHSCF-NH2, Syringe 5: Ao-PHSCY-NH2, Syringe 6: Ac-PHSRY-NH2 
Amino Acids Added Syringe 1 Syringe 2 Syringe 3 Syringe 4 Syringe 5 Syringe 6 
(0.54mmol) 
Boc-Asn-OH (125.4 mg) Cycle 1* 
Boc-Phe-OH (143.3 mg) Cycle 1 Cycle 1 Cycle 1 
Boc-Try(2,6-diCI-Bn)-OH 




Boc-Asp(OBn)-OH (174.6 mg) Cycle 2 
Boc-Cys(pmb)-OH (184.4 mg) Cycle 2 
Boc-Arg(Tos)-OH (231.4 mg) Cycle 2 Cycle 2 
Boc-Ser(Bn)-OH (158.9 mg) Cycle 3 Cycle 3 Cycle 3 Cycle 3 Cycle 3 Cycle 3 
Boc-His(Tos)-OH (213.1 mg) Cycle 4 Cycle 4 Cycle 4 Cycle 4 Cycle 4 Cycle 4 
Boc-Pro-OH (180.1 mg) Cycle 5 Cycle 5 Cycle 5 Cycle 5 Cycle 5 Cycle 5 
*Cycle means each cycle addressed in Table 5 
(5) Solid phase hydroxamate peptide synthesis of Ac-Pro-His-Ser-
Glu(NHOH)-Leu-NH2 (1) 
(i) Preparation of Fmo-Glu(OtBu)-Leu-MBHA resin (25) 
The reaction started from 200 mg (0.19 mmol) ofMBHA resin (substitution= 1.2 
meq/g) swelled in DIEA/DCM: 1/9 overnight. Boc-Leu-OH (142.1 mg, 0.57 mmol) was 
coupled to the resin with BOP (252.2 mg, 0.57 mmol), HOBt (77 mg, 0.57 mmol) and 
DIEA (0.20 mL, 1.14 mmol). TFAlDCM/anisol (45/50/5) (10 mL) was used to remove 
the N<l-Boc group. Fmoc-Glu(OtBu)-OH (404.2 mg, 0.95 mmol) was coupled to the resin 
with BOP (420.3 mg, 0.95 mmol), HOBt (128.4 mg, 0.95 mniol) and DIEA (0.3 mL, 1.90 
mmol). 
(ii) Preparation of Fmo-Glu(NHOBn)-Leu-MBHA resin (26) 
The t-Butyl group was removed by 10 mL TFA/CH2Ch/anisole (65/30/5) for 30 
min and for three times in together. NH20Bn . HCI (151.6 mg, 0.95 mmol) was coupled 
to the resin under the activation of coupling reagents BOP (420.3 mg, 0.95 mmol), HOBt 
(128.4 mg, 0.95 mmol) and DIEA (0.3 mL, 1.90 mmol). 
(iii) Preparation of Ac-Pro-His(Trt)-Ser(tBu)-Glu(NHOBn)-Leu-MBHA resin 
(27) 
Resin 26 was treated with 25% piperidinelDMF for 30 min and washed with 
DMF, MeOH and DCM. Fmoc-Ser(tBu)-OH (364.3 mg, 0.95 mmol) and Fmoc-His(Trt)-
OH (622.9 mg, 0.95 mmol) and Fmoc-Pro-OH(320.5 mg, 0.95 mmol) were coupled to 
the resin one by one in classic Fmoc cycle. The coupling reagents used were BOP (420.3 
mg, 0.95 mmol), HOBt (128.4 mg, 0.95 mmol) and DIEA (0.3 mL, 1.90 mmol) in 8 mL 
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DMF. After Fmoc on Proline was removed, the peptide was acetylated shaking with 1 
mL, 5.4 mmol acetic anhydride and 0.5 mL, 2.8 mmol DIEA in 10 mL DCM overnight. 
(iv) Preparation of Ac-Pro-His-Ser-Glu(NHOH)-Leu-NH2 (1) 
The dry hydroxamate peptide resin was put into a Kel-F HF apparatus and stirred 
with 5 mL anhydrous HF and 0.05 mL anisole at 0 °C for Ih. HF was evaporated and the 
solid was washed with ether (20 mL X 3). The peptide was extracted by 25% acetic acid 
and crude peptide was obtained after lyophilization. The crude peptide was purified by 
running through C-18 column and eluted with 10% acetonitrile, and purified peptide (94 
mg) was obtained, which can change FeCl) test solution from yellow to red. Yield: 78%. 
RP-HPLC Rt (min): 12.1 
MALDI-MS: calc. (C27H43N909) 637.3, found (M+H), 638.5 
(6) Ac-Pro-His-Ser-Glu(NHOH)-Asn-NH2 (2) 
(i) Preparation of Boc-Asn-MBHA resin (28) 
Boc-Asn-OH (132.4 mg, 0.57 mmol) was coupled to 200 mg (0.19 mmol) the 
swelled MBHA resin with coupling reagents: BOP (252.2 mg, 0.57 mmol), HOBt (77.0 
mg, 0.57 mmol) and DIEA (0.20 mL, 1.14 mmol). 
(ii) Preparation of Ac-Pro-His-Ser-Glu(NHOH)-Asn-NH2 (2) 
By following the method of peptide 1 synthesis, the peptide Ac-Pro-His(Trt)-
Ser(tBu)-Glu(NHOBn)-Asn-MBHA was prepared. After HF cleavage, crude peptide was 
obtained as brown solid in 110 mg. Purified compound (97 mg) was collected as light 
yellow powder after chromatograph. Yield: 80%. 
RP-HPLC Rt (min): 5.35 
MALDI-MS: calc. (C2sH38NIOOIO) 638.3, found (M+H), 639.9 
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(7) Ac-Pro-His-Ser-Asp(NHOH)-Asn-NH2 (3) 
(i) H-Pro-His(Trt)-Ser(tBu)-Asp(OIBu)-Asn(Xan)-MBHA resin (29) 
The reaction started from 200 mg, 0.24 mmol MBHA resin. Boc-Asn(Xan)-OH 
(296.3 mg, 0.72 mmol) was coupled to the resin, and Boc group was removed by TF AI 
DCMI anisole (50/45/5). Fmoc-Asp(OIBu)-OH (296.3 mg, 0.72 mmol), Fmoc-Ser(tBu)-
OH (276.1 mg, 0.72 mmol) and Fmoc-His(Trt)-OH . 0.6 isopropanol (472.1 mg, 0.72 
mmol) and Fmoc-Pro-OH (242.9 mg, 0.72 mmol) were coupled to the resin one by one in 
classic Fmoc cycle. BOP (318.6 mg, 0.72 mmol), HOBt (97.3 mg, 0.72 mmol) and DIEA 
(0.25 mL, 1.44 mmol) were included as coupling reagents in each cycle. Piperazine in 
DMF (6% w/v) was used to deprotect Fmoc group after each coupling. 
(ii) Ac-Pro-His-Ser-Asp(NHOBn)-Asn(Xan)-MBHA resin (30) 
Acetic anhydride (I mL, 5.4 mmol) was used to acetylize the peptide. The t-Butyl 
side chain protecting group of aspartic acid was removed by TF AI DCMI anisole (701 251 
5) treatment for three times and 30 min each time, before the resin was coupled with 
NH20Bn (115 mg, 0.72 mmol), BOP (318.6 mg, 0.72 mmol), HOBt (97.3 mg, 0.72 
mmol) and DIEA (0.25 mL, 1.44 mmol). The TF A deprotection also removed the Tos 
group on histidine and t-butyl group on serine. 
(iii) Ac-Pro-His-Ser-Asp(NHOH)-Asn-NH2 (3) 
HF cleavage of the peptide provided the crude product in 125 mg as yellow 
solid. After chromatograph purification, 100 mg light yellow powder was obtained. 
(Yield: 68%) 
RP-HPLC Rt (min): 4.11 
MALDI-MS: calc. (C24H36NIOOIO) 624.3, found (M+H) 625.3 
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CHAPTER II 
SYNTHESIS AND METAL BINDING STUDIES OF PEPTIDE SIDEROPHORE 
ANALOGUES 
A Introduction 
Metals have played an essential role in the evolution of every form of life on 
earth. However, most of the metal elements are present in non-utilizable inorganic forms, 
so nature has prepared vehicles to convey metals for living creatures. Ionophores are 
recognized as being one of the most special and efficient of such vehicles. Based on the 
Collins English Dictionary, an ionophore is "a chemical compound capable of forming a 
complex with an ion and transporting it through a biological membrane". Siderophores, 
natural ionophores which can bind iron and transfer it from an aqueous medium into a 
hydrophobic phase, have been the subject of intense reseruch for many years. 
1. General Introduction of Siderophores 
Iron is required by most biological systems due to its diverse roles in the 
biochemistry of the cell. Although it is one of the most abundant elements on the planet, 
the bioavailability of iron is very poor, because the predominant form of iron occurs in its 
oxidized ferric [Fe (III)] state, which is highly insoluble at physiological pH. To 
circumvent the solubility problem, many microbial, plants and even higher organisms 
secrete specific low molecular weight iron chelators called siderophores (iron carriers) to 
sequester and transport iron (Clarke, 2001). 
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In nature, bacteria or neighboring microorganisms produce siderophores which 
chelate the iron from transferrin, lactoferrin or other iron-binding proteins (Clarke, 2001). 
The siderophore can then be transported into the cell (through the outer membrane, across 
the periplasm and inner membrane) via specific membrane-bound uptake systems. The 
whole transportation process involves a stereospecific and enantioselective recognition of 
the ferric complex by receptor proteins at the cell surface (Clarke, 2001). 
Iron in its trivalent state has a d5 electronic configuration and the coordination 
requirements of iron(III) are best satisfied by six donor atoms ligating in an octahedral 
fashion to the metal center. Therefore, iron complexes are preferentially hexacoordinate, 
quasi octahedral. Fe(III) can form 1:3 complexes with bidentate ligands, 1:2 complexes 
with tridentate ligands, and a 1: 1 complex with a hexadentate ligand. In siderophores, 
sixfold coordination is mostly achieved by trisbidentate ligands, because the complex can 
obtain the maximal thermodynamic stability by incorporating all six donors into a single 
molecular structure (Liu and Hider, 2002). Outstandingly stable iron complexes are 
formed with these hexadentate ligands: tricatecholate siderophores have complex 
formation constants up to 10g"Kf = 52 (Harris, 1979), trihydroxamates have formation 
constants around 1030 [L . mor i ], dihydroxamatel carboxylates are about 1023 [L . mor i ], 
and the constant for pure carboxylate is approximately 102i [L· mori] (Crumbliss, 1991) 
(Reid, 1993). 
The donor atoms in ferric siderophore complexes are primarily oxygen and, 
rarely, heterocyclic nitrogen in accordance with HSAB (hard/soft-acid/base) principle. 
Since ferric ion is a hard acid which is preferentially linked to hard base atoms, such as 
oxygen, as coordination partners. On the other hand, iron(III) is a spherically symmetrical 
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cation of radius 0.64 A with high charge density; therefore, it forms the most stable bonds 
with weakly polarizable oxygen atoms (Liu and Hider, 2002). 
2. Molecular Diversity of Siderophores 
More than a hundred naturally-occurring siderophores have currently been 
identified and characterized. These ligands involve two major functional groups: 
hydroxamates and catecholates. Ferrichrome, coprogen, ferrioxamine and rhodotorulic 
acid are representative hydroxamate siderophores. Also, phenolate siderophores include 
enterobactin, the strongest iron (III) chelator analogues, pyoverdins, pseudobactin, 
mycobactin and pyochelin (Miller, 1989). 
(1) Hydroxamate Siderophores 
Derived from Streptomyces pilosisand, desferrioxamine is the most well-known 
example among the hydroxamic acid siderophores (Figure 21). Desferrioxamine-B 
(clinically as Desferal™) has been widely used in treating hemochromatosis, acute iron 
poisoning (Cooley's anemia), and iron overload over the past 30 years (Miller, 1989). 
Desferrioxamine has three hydroxamate functional groups and behaves as a hexadentate 
ligand, forming a I: 1 (molar ratio) complex with iron. Additionally, desferrioxamine has 
a high selectivity towards iron(III) compared to other metal ions present in biological 
fluids, such as zinc, calcium and magnesium. However, the oral inactivity and rapid renal 
clearance of desferrioxamine make it less than an ideal therapeutic agent. Medicinal 
chemists are still investigating the appropriate way to improve the oral bioavailability of 
desferrioxamine, including prodrug preparation and backbone modifications. Metaphore 
Pharmaceuticals has developed solid-phase approaches to the synthesis of 
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desferrioxamine variant libraries for high-throughput screening for their metal-binding 
properties (Marshall, 2002). 
Figure 21 Structure of desferrioxamine B 
(2) Phenolate Siderophores 
With the highest reported iron-binding capacity of all siderophores, enterobactin 
is one of the best-studied siderophores. Originally isolated from E. coli and also found in 
many other enterobacteriaceae, enterobactin is a tricatecholate siderophore with a ferric 
complex formation constant of 1052 [L . mor l ] (Pollack and Neilands, 1970). This 
siderophore is a cyclic triester of serine acylated with 2, 3-dihydroxybenzoic acid and 
three residues of dihydroxybenzoic acid provide the chelating groups (Figure 22) 
(Drechsel and lung, 1998). 
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Figure 22 Structure of enterobactin 
(3) Mixed Metal Binding Site Siderophores 
Pyoverdins (also named pseudobactins), siderophores found in Pseudomonas 
aeruginosa, are potent Fe3+ chelators with complexing constants between 1024 and 1026 
[L.mor l ] at pH 7.0. Pseudomonas genus belong to the "fluorescent" sub-group in the 
rRNA homology group I of the family Pseudomonadaceae. The "fluorescents" derived 
their name from their ability to produce compounds under iron-deficient growth 
conditions showing a yellowish-green fluorescence (Budzikiewicz, 2001). The 
conspicuous fluorescence of pyoverdins arises from a chromophore with the core 
structure of 2, 3-diamino-6,7-dihydroxyquinoline (Figure 23). Pyoverdins are defined as 
mixed metal binding ligands, as those complexes contain metal binding sites including 
the catecholate group as a chromophore and two amino acids, hydroxamic acids and! or 
hydroxycarboxylic acids as bidentate ligand sites. Compounds involved in this 
classification all have the common (1 S)-5-amino-2,3-dihydro-8,9-dihydroxy-l H-
[1,2a]chinolin-l-carboxylic acid chromophore. Also common to these compounds is the 
substitution of the 5-amino group with different carboxylic acids, such as succinic acid, 
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malic acid, 2-oxo-glutaric acid or glutamic acid the amine group of which could also be 
connected to a peptide chain with 6-12 amino acids (Drechsel and Jung, 1998). 
The siderophores azotobactins and ferribactins show a high similarity to 
pyoverdins; by sharing the same peptidic component but having different chromophores. 
Azotobactin's chromophore has an imidazolone ring fused with a quinoline ring. Lacking 
the chromophore of pyoverdin, ferribactin contains a cyclization product of Tyr/Dab 
instead (Figure 23) (Drechsel and Jung, 1998). 
Figure 23 
ferribactin 










Chromophores of pyoverdins, azotobactins and ferribactins 
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Pyoverdin 
Mycobactins are a family of siderophores, which are isolated from mycobacteria 
including Mycobacterium tuberculosis and Mycobacterium phlei. This family promotes 
mycobacterial growth via iron uptake processes. From the general structure, one can see 
that mycobactins possess a nearly identical molecular metal binding site, including two 
hydroxamic acids and a 2-(2-hydroxyphenyl)-1,3-oxazoline residue serving as the iron 
chelator (Figure 24) and vary only in the stereochemistry of the chiral centers and in the 
peripheral groups (Hu, 1997). Based on Snow's findings, the three hydroxyl groups, 
chelated iron to form a stable complex which was necessary for mycobactin's biological 
activity. Loss of the growth inhibitory or stimulatory activity was observed for synthetic 
analogues without the hydroxyl groups. The long lipophilic side chain is essential for 
mycobactins to transport iron through cell membranes, making it a potential drug carrier 
(Snow, 1970; Snow, 1965). 
Figure 24 Structure of Mycobactin 
(4) Carboxylate Siderophores 
Besides the hydroxamates, catecholates and mixed-ligand complexes, a new class 
of siderophores was isolated from various yeasts. These siderophores contain only 
aliphatic amines and lor carboxylate and hydroxyl donor groups as chelating ligands 
(Carrano, 1996). Rhizobactin DM4 (rhizoferrin, Figure 25) is the first representative of 
the carboxylate class of these siderophores and was originally isolated from Rhizopus 
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microsporus by Neiland and his coworkers in 1985 (Smith, 1985). Rhizoferrin strongly 
binds and transports iron into the cell as do other siderophores; however, the coordination 
chemistry of the rhizoferrin iron complex is not well understood. The detailed mechanism 
of rhizoferrin-mediated transport by microorganisms is also under study (Carrano, 1996; 
Thiken, 1992). 
Figure 25 Structure of rhizoferrin 
(5) Peptide Siderophores 
By reviewing the diverse structure of siderophores, we can find that many of them 
contain peptidic building blocks and some siderophores contain oligopeptides. The 
peptide side chains are available for complexation to ferric ions, such as the 
aforementioned pyoverdins. Among the amino acids attached to the chromophore, N5_ 
acetyl-N5 -hydroxy-ornithine and threo-p-aspartic acid provide the second and third 
bidentate iron chelating sites besides the catecholate. Among the siderophores with side-
chain-connected amino acids along their backbone, coprogens have the diketopiperazine 
ring of two N5 -acylated-N5 -hydroxylated ornithine as the basic structure (Figure 26) 
(Drechsel and Jung, 1998). 
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Figure 26 Structure of coprogen 
Enterobactin is a trimer of 2,3-dihydroxybenzoyl-L-serine (Figure 22), which 
complexes ferric ion as a hexadentate ligand. For the free ligand, by using three internal 
H-bonds of the amide protons to the lactone oxygen of the same serine, a cavity for 
complexing ferric ions is preformed. When ligand binding to ferric ions occurs, the H-
bonds are shifted to the catecholate oxygens (ortho position) (Shanzer and Libman, 
1991). 
Cyclized amino acids were also observed in siderophore structures. A 5-
methyloxazoline ring was found to be the common linker between hydroxylbenzoic acid 
and the dialkyl imide backbone in agrobactin (Figure 27), parabactin and fluvabactin. All 
of these siderophores have cyclized L-threonine, and some of those compounds have 
tricatecholate groups. For the non tricatecholate system, such as parabactin, the oxazoline 
nitrogen would also be involved in iron chelating as well as L-threonine. 
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Figure 27 Ligand site of agrobactin (R= OH), parabactin (R= H) and fluvabactin 
(R=OH) 
3 Siderophore Detection 
Iron chelating capability can be proven by physiochemical means. When 
transition metals fonn complexes, charge transfer bands usually occur which give the 
complexes visible color. In the case of ferric complexes, charge transfer bands are seen 
between 350 and 650 nm. These complexes can be visually detected as yellow-brown to 
red-brown compounds. In the classic FeCh test, the color of the solution changes from 
yellow to dark red once the hydroxamate iron complex is formed. 
The chrome azurol sufonate assay has also been widely used for siderophore 
detection, because this test is comprehensive, exceptionally responsive and convenient. 
The chrome azurol sulfonate assay can be applied on agar surfaces or in solution. The 
assay is based on the color change that accompanies transfer of the ferric ion from an 
initial intense blue complex to the siderophore (Neilands, 1995). 
4 Methods for Metal Binding Assay 
Metal affinity chromatography was developed by Belfrage's group as a new 
approach for protein fractionation. This technique is based on the ability of proteins to 
bind metal ions immobilized on chelate gels (Porath, 1975). Volz and his coworkers 
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successfully applied this technology in investigating the metal selectivity of HxH and 
CxxC polypeptides. Nitrotriacetic acid (NT A) agarose was preloaded with various metal 
chlorides and packed into a column before the column was connected to a protein liquid 
chromatography system. The polypeptide was applied to the NT A columns and the 
elution fractions were analyzed by sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-P AGE) to detect metal binding peptides (Volz, 1998). Also 
quantitative metal ion affinity chromatography can be used to determine peptide-metal 
ion interaction stoichiometry. 
(1) Electrospray Ionization- Mass Spectrometry (ESI-MS) 
ESI mass spectrometry has been shown to be a powerful method for the 
characterization of non-covalent complexes of biomacromolecules (Przybylski, 1996). 
The gentleness of electrospray ionization allowed detection of very weakly associated 
complexes under the proper experimental conditions (Brewer, 2000). Once several 
parameters including pH, ionic strength, temperature and source voltage parameters were 
carefully controlled, the ionization and volatilization process of ESI-MS did not lead to 
complex decomposition. As a result, ESI-MS has been used to characterize non-covalent 
complexes by Dorsselaer and his coworkers (Jaquinod, 1993). The affinity of metal ions 
to peptide sequences could be found by observing molecular mass ions, and the 
selectivity of peptide to metals was determined by measuring the abundance of molecular 
ions. (Przybylski, 1996) 
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(2) Tandem Mass Spectrometry (MSIMS) 
Tandem mass spectrometry (MS/MS) is a technique in which a precursor ion is 
isolated, which then undergoes a fragmentation to yield product ions and neutral 
fragments: 
+ + 
mp ~ md + 
In the technique of MS/MS one mass spectrometer is coupled to a second 
spectrometer. The molecular ions are isolated by the first mass spectrometer from a 
sample mixture. Parent ions are then subjected to a second fragmentation to form a 
multitude of daughter ions and give a series of mass spectra, one for each molecular ion 
produced in the first spectrometer. The spectrum of these daughter ions is then scanned 
by the second spectrometer. One such instrument uses three quadrupoles, the first and the 
third of these function as spectrometers. The central one acts as an inert gas collision cell 
(CC) made up of a quadrupole using radio frequency (RF) only as a means of ion 
focusing. Besides the fragment (daughter)-ion MS/MS, the precursor (parent)-ion 
MS/MS is also utilized in tracking the parent peaks of the known fragment peak. In this 
technique the first spectrometer is scanned while the second spectrometer is set to the 
mass of one of the daughter ions. 
Multistep tandem mass spectrometry (MSn) has been widely used in metal 
binding ligand characterization. Gross and Ngoka have successfully defined the metal 
binding sites on cyclic peptides by using MSIMS (Ngoka, 2000). The metal-containing 
cyclic peptide was subjected to multiple stages of collisionally activated decomposition 
(CAD) in an ion trap mass spectrometer. Upon collisional activation one amide bond was 
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cleaved and the metal ion acted as a fixed charge site to direct a charge-remote, sequence-
specific fragmentation of the ring-opened peptide. 
(3) Matrix Assisted Laser Desorption Ionization - Time of Flight Mass 
Spectrometry (MALDI-TOF MS) 
. MALDI mass spectrometry is the offspring of the direct laser desorption (LD) 
mass spectrometry of small molecules and was first described by Karas and Hillenkamp 
in 1988 (Karas, 1988). This technique has become one of the most successful methods for 
the identification of various biologically active substances including proteins (Karas, 
1989), oligosaccarides (Stahl, 1991), oligonucleotides (Overberg, 1992) and polymers 
(Baht, 1992). MALDI-MS is highly sensitive, and requires only femtomoles of sample. 
Mass accuracy is of 0.1-0.2% and can be improved to the level of 0.01% with the use of 
internal calibrants (Cohen, 1996). Theoretically it can analyze unlimited mass range, up 
to 106 daltons (Da). From a single ionization event, a complete set of mass spectra can be 
obtained, and substances can be identified from mixtures without previous fractionation. 
MALDI-TOF MS is extensively used in qualitative analysis; however, the 
quantitation of proteins and peptides by this method is still very difficult. Significant 
variations in the ion signals obtained from consecutive laser shots, as well as from 
different spots in a given sample, complicate the direct quantification of analytes. These 
variations are due to non-homogeneous co-crystallization of matrix and sample 
molecules, fluctuations in laser power, and changes in detector response. The absolute 
intensities of the detected ions also depend on their chemical nature, although some 
suppression effects have been described (Beavis, 1990). All of these bring difficulties to 
quantitative analysis of proteins and peptides by MALDI-TOF MS. Internal standards 
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have been used in the quantitation step to help overcome these problems. Jespersen found 
a linear correlation between the peak height ratio and the sample loading when similar 
proteins or peptides were used as internal standards. To maintain the accuracy for 
quantitation, the analyte and internal standard need to have the same chemical properties 
(Jespersen, 1995). The Mirgorodskaya group introduced stabilized ISO-labeled internal 
standards for the quantitative analysis of proteins and peptides by hydrolyzing proteins or 
peptides in ISO-water (Mirgorodskaya, 2000). Then an ISO-labeled standard was mixed 
with the corresponding unlabeled substance of unknown concentration. The isotopic 
pattern of the mixture could reflect the relative concentration of unlabeled compound and 
labeled standard (Mirgorodskaya, 2000). 
A commonly used alternative quantitative method is normalization. This approach 
does not require the use of internal standards and is much simpler. Blair and his 
coworkers used the correction factor to normalize the peak intensity and enable MALDI-
TOF MS to evaluate the binding selectivity of hosts. The binding selectivity was reflected 
in the intensities of the complexes after a correction factor of 1.4 was normalized to the 
intensity of every peak (Blair, 1998). The metal selectivity ratio obtained from the 
MALDI measurements agreed with the ratios obtained from comparable ESI experiments 
(Goolsby, 1999). However, this normalization method assumed that each sample 
component gave rise to a peak in the spectrum and the detector response was equivalent 
for all compounds. 
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B. Research Objectives 
Earlier work in our lab demonstrated that a cyclic heptapeptide with a dipeptide 
tail is a particularly effective host for a Ca2+ ion. A three-component, cyclohexapeptide 
mixture did not show any significant difference with respect to binding metal ions. This 
result also demonstrated that preferential binding of metal ions for a certain ligand could 
be detected by using a mixture of metal ions via competition F AB-MS studies (Chen, 
1996). 
This current work focused on the preparation of specific linear symmetric 
hexpeptides as selective siderophore analogues. Chiral amino acids were utilized to fix 
the stereochemistry of the side chains in well-defined and known positions, and the 
ligand binding sites were introduced into peptides by incorporating amino acids with 
metal binding side chains (glutamic acid or hydroxamate glutamic acid). Our approach 
used mass spectrometry as a semi-quantitative method to evaluate the metal binding 
abilities of peptide ligands and used an MS/MS technique to explore ligand metal binding 
modes. Relative peak abundances of peptide-metal ion adducts compared to free peptides 
were used as qualitative evidence for binding preference of the metal ions. 
C. Results and Discussion 
1. Peptide Synthesis 
Siderophore analogues, linear hexapeptide E and peptide H, containing amino 
acids with negatively charged side chains were designed and synthesized to explore metal 
binding capability and metal binding selectivity of these peptides. 
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The target sequences were peptide E with the structure of Ac-GlYI-Glu2-D-Pro3-
GlY4-Glus-D-Pro6-NH2 and peptide H with the structure of Ac-GlYI-Glu2(NHOH)-D-
Pr03-GlY4-Glus(NHOH)-D-Pro6-NH2 (Figure 28). These peptides were composed of the 
amino acids in a repetitive sequence to provide some symmetry to the peptide chain, 
because symmetric structures are commonly observed in natural ionophores. Two proline 
residues were incorporated to induce turn conformations, which are also a common 
structural feature of many natural ionophores. The potential metal binding sites were 
provided by amino acids with carboxylate groups and hydroxamate group side chains in 
both peptides. In peptide E, two carboxylic acid groups on the glutamic side chains can 
function as metal chelators after being deprotonated. In peptide H, the strong metal 
chelator, the hydroxamic acid group, was substituted for each of the carboxylic acids on 
the glutamic acid side chains to determine whether the introduction of a hydroxamic acid 
residue would change the peptide metal binding capability and metal selectivity. The 
metal binding selectivity was tested by mass spectrometry and metal binding modes were 
explored by using MS/MS. 
Peptide E (Ac-GlYI-Glu2-D-Pro3-GlY4-Glus-D-Pro6-NH2) 
Peptide E was prepared by using Boc chemistry in solid phase peptide synthesis. 
To obtain a C-terminal amidated peptide, the peptide chain was built on a pMBHA resin, 
and the amino acid building blocks used were Boc-D-Pro-OH, Boc-Glu(OBn)-OH and 
Boc-Gly-OH. HF was used to cleave the peptide from the resin after peptide chain 
elongation and N terminal acetylation. The peptide was purified by eluting through a CI8 
reverse phase column with waterl acetonitrile solvent. 
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Peptide H (Ac-GlYI-Glu2(NHOH)-D-Pr03-GlY4-Glus(NHOH)-D-Pr06-NH2) 
Peptide H (dihydroxamate peptide) was synthesized by following the hydroxamic 
acid peptide solid phase synthesis method (Figure 29) discussed in Chapter 1. Fmoc 
chemistry was used to build the peptide chain followed by prolonged TF A treatment to 
deprotect the OtBu protecting group on glutamic acid. The unprotected carbonyl group 
was then available for further modification. BnONH2'HCI was condensed with BOP and 
DIEA, which resulted in Ac-Gly-Glu(NHOBn)-D-Pro-Gly-Glu(NHOBn)-D-Pro-resin, 
and the Bn group was simultaneously removed when the peptide was cleaved from the 
resin by HF. 
Figure 28 Structure of peptide E and peptide H 
Peptide H Peptide E 
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Figure 29 Solid phase synthesis of peptide H 
Fmoc-D-Pro-NH2 + 
BOP, HOBt, DIEA in DMF 
--------.. Fmoc-D-Pro-
I) Piperidine! DMF (I! 4) .. Fmoc-Gly-Glu(OIBu)-D-Pro-Gly-Glu(OIBu)-D-Pro 
SPPS, Fmoc cycle ( five times) 
I) Piperidine! DMF (1/4) 
Ac-Gly-Glu(OIBu)-D-Pro-Gly-Glu(OIBu)-D-Pro-Q 
2) Acetic Anhydride, DIEA in DCM 
I) TF AI DCM! Anisole (70!25! 5), 3 X 30min 
2) 10% DIEA in DMF ~ 
-------------~ .. ~ AC-Gly-Glu(NHOBn)-D-Pro-Gly-Glu(NHOBn)-D-Pro-.." 
3) NHpBn, BOP, HOBt, DIEA in DMF 
HF, anisole .. Ac-Gly-Glu(NHOH)-D-Pro-Gly-Glu(NHOH)-D-Pro-NH2 
2. Metal Binding Studies with Peptide E (Ac-GlYt-Glu2-D-Pro3-GlY4-
Glus-D-Pro6-NHz) with MALDI-TOF MS 
In the following mass spectrometry study, "L" was used to stand for free peptide 
E molecule. First, the free ligand peptide E was subjected to MALDI-MS. A [L + Ht 
(m/z= 625) molecular ion peak was not detected in spectrum (Figure 30d); instead [L + 
Nat and [L + Kt ions were the prominent peaks at m/z 648 and 664, respectively, 
indicating the samples were possibly contaminated by the alkali metals from glass 
surfaces. When we ran the same sample on an ESI-MS instrument, the [L + Ht peak was 
clearly observed and peptide adducts with sodium and potassium were much less 
significant (Figure 32). In this case, ESI-MS appears to be a more appropriate instrument 
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than MALDI-MS, because ESI-MS allows the detection of free ligand without capture of 
alkali metal ions from the environment. 
In the evaluation of peptide E metal binding capability, peptide E was combined 
with single metal ions by mixing equimolar quantities of metal perchlorate salt 
Each complex sample was combined with an excess of a-cyano-4-hydroxycinnamic acid 
. matrix in a water (0.1 % TF A)/ acetonitrile (1 :2) solution and allowed to air dry before 
being tested by the MALDI-TOF MS. 
Figure 31 (spectra A-C) illustrates the MALDI-MS data of peptide E binding a 
single metal ion (Ni2+, Zn2+ and Fe3+ respectively). The expected ligand metal complex 
experiments, and [L + Nat and [L + Kt ions were also detected in each mass spectrum. 
Figure 30 shows the proposed peptide E metal binding modes to Ni2+, Zn2+ and Fe3+. 
Since both Ni(H) and Zn(H) are doubly charged ions and bind the metal in a similar 
fashion (Figure 30), then the two Glu anions neutralize divalent metals and therefore the 
complex requires additional protonation for the ligand. However, this is no longer the 
case with Fe3+ and the masses observed agree with this interpretation. 




Figure 31 MALDI-MS studies of peptide E (L) (Ac-Gly-Glu-D-Pro-Gly-Glu-D-Pro-NH2) (31d) and peptide E (MW= 625) 
with single metal ion (31a: peptide E • Zn2+, 31 b: peptide E • Ni2+, 31c: peptide E • Fe3+) 
a 
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3 Metal Binding Studies of Peptide E(Ac-GIYI-Glu2-D-Pro3-GIY4-Glus-D-Pro6-
NH2) Using ESJ-MS 
As mentioned before, the free ligand peptide E molecular ion [L + Ht ion was 
clearly observed in the ESI-MS spectrum, and [L + Nat and [L + Kt peaks were almost 
undetectable (Figure 32). 
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(1) Peptide E Binding with Single Metal Studies 
In our peptide ~etal complex experiment, equimolar amounts of metal 
perchlorate salt and peptide E were dissolved in a 1: 1 water-acetonitrile solution. In a 
subsequent peptide metal binding competitive experiment, metal perchlorate salt mixtures 
were prepared with different ratios, which were dissolved in 1: 1 water-acetonitrile 
solution, followed by the introduction of peptide E with the desired concentration into the 
solution. To achieve good ionization under the electrospray, formic acid was also added 
to each sample to adjust pH to 5 before being subjected to ESI-MS, therefore assuming 
partial protonation of glutamyl side chains. The peak abundances of the free ligand ion 
and ligand-metal adduct ions were recorded. The relative stability of the ligand-metal 
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adducts was evaluated by relative peak abundance (RP A), which is defined in this case as 
the ratio of peptide-metal complex peak height to free peptide peak height. Peptide E 
single metal complex results are summarized in Table 8, while Table 9 contains the 
results of the peptide E competitive metal binding studies. Although the RP A value 
cannot be considered in any way a quantitative measure of metal ion binding, this value 
could be used as a semi-quantitative index to probe the most predominant species among 
the complex mixtures in one experiment. 
Figure 38b, 40b and 42b illustrate ESI-MS data of peptide H . Ni(II), peptide H . 
Zn(II) and peptide H . Fe(III) respectively, which are largely different from the MALDI-
MS experiment of the same species. Although we did observe the expected peaks for [L + 
Ni2+ - H+t at 682, [L + Zn2+ - H+t at 688 and [L + Fe3+ - 2H+t at 679 in their respective 
experiments, which were also found in earlier MALDI-MS experiments (Figure 31a-c), 
all these peaks were in much lower intensity compared to the peaks of [L + Ne+]2+ at 342, 
[L + Zn2+]2+ at 345 and [L + Fe3+_H]2+ at 340 in single metal ligand complex ESI-MS 
study. Summarized in Table 8, the RP A values of the doubly charged ions peaks were 
several hundred times larger than the RP A of singly charged adducts, which demonstrates 
that the doubly charged complex ions were the most abundant species in ESI mass 
spectra. This unique phenomenon was only observed in the ESI-MS study and did not 
occur in MALDI-MS study. A possible explanation could be that these doubly charged 
species arose during the ionization process, from the electro sprayed droplets, where 
evaporation would presumably lead to higher concentrations and alter solution 
conditions. Singly charged complex molecules obtained one more proton and were shown 
as the divalent charged species in ESI-MS. 
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For peptide E· Ni2+ and peptide E· Zn2+ complexes, a perchlorate ion adduct was 
also observed (Figure 39d and Figure 41c). In the complex of peptide E binding nickel, a 
doubly charged peptide-metal-peptide sandwich complex with a mass of 1308.8 (mlz = 
654.4) was detected (Figure 38b and 39d). 
Comparing the results of MALDI-MS and ESI-MS, we found that ESI-MS is a 
better tool to study the non-covalent complex, which was also proved by Pramanik group 
who utilized ESI-MS for the study of non-covalent protein-metal complex [HCV (1-181)-
ZnJ (Pramanik, 1998). Using ESI-MS allowed us to study metal-protein interactions in 
solution, since in a metal ligand complex system, pre-existing ions in solution could be 
observed directly as a consequence of the soft transfer to the gas phase. Although 
MALDI-MS has been recognized as an effective method in intact peptide/ protein 
detection, the ambiguity of adduct attachment of ligand and metal determined the 
disadvantage ofMALDI-MS in metal ligand complex study. 
(2) Peptide E Ligand Competitive Metal Binding Studies 
In competitive metal binding studies, the doubly charged metal ligand adducts are 
still the predominant forms in metal peptide complexes, which is in agreement of single 
metal binding test, although the peaks were presented in relative low resolution (Figure 
43a and 43e). Therefore we used relative peak abundances of [L + Mf+ (M: Ni or Zn) 
(adduct peak intensity vs free peptide peak intensity) to evaluate the metal affinities to the 
peptide (Table 9) (Figure 43e). Peptide E contains a carboxylate side chain and has the 
metal binding potential to some degree, which is shown in MS study; however, the metal 
preference is not obvious, and the slight selectivity of the peptide E for metal ions was 
found to be Ni2+ > Zn2+ > F e3+. 
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Table 8 Peptide Ac-Gly-Glu-D-Pro-Gly-Glu-D-Pro-NH2 (L) metal binding assay 
in individual tests by ESI-MS 
Peptide metal [Adduct]/[m+H+r 
Peak found (mlz) Adduct fonnation 
ion complex (RPA) 
679.4 [L + Fe3+ - 2H+r 0.03 
L + Fe3+ 340.3 [L + Fe3+ - wf+ 4.03 
685.7 Undetennined 0.15 
688.4 [L + Zn2+ - H+r 0.43 
344.7 
L + Zn2+ 
[L + Zn 2+]2+ 53.13 
788.3 [L + (ZnCI04tr 0.48 
657.4 U ndetennined 0.48 
682.4 [L + Ni2+ - H+r 1.23 
341.8 
L + Ni2+ 
[L + Ni 2+]2+ 426.82 
654.4 [L+Ni 2++L]2+ 7.41 
782.3 [L + (NiCI04tt 3.22 
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Table 9 Using ESI-MS to assess peptide E (L) metal binding with a mixture of 
metal ions in competition experiment 
Peptide metal [Adduct ]/[L + Itt 
Peak found (m/z) Adduct formation 
complex (RPA) 
679.36 [L + Fe3+ - 2H+t 0.05 
L + Fe3+ 340.26 [L + Fe3+ _ H+]2+ 6.63 
685.69 Undetermined 0.10 
688.35 [L + ZnZ+ - H+t 0.06 
L + Zn2+ 
344.78 [L + Zn 2+]2+ 9.54 
682.38 [L + Ni2+-H+t Undetectable 
L + Ni2+ 
341.77 [L + Ni2+]2+ 12.06 
(3) Peptide E . Metal Ion Complexes Structures 
In this study we also attempted to elucidate the geometry structures of peptide E 
metal complexes based on the obtained MS results and the known metal ion coordination 
characters. A dB NiH ion can exist in six coordinate octahedral and four coordinate 
tetrahedral or square planar geometries depending on the ligand-field splitting of the 
center metal. The diamagnetic (low spin) Ni(lI) would have a square-planar geometry, 
and both tetrahedral and octahedral d8 Ni(lI) complexes usually have two unpaired 
electrons and would be paramagnetic (high spin). Many nickel (II) complexes tend to 
form an equilibrium among several geometries. A famous example is the Lifschitz salt, 
nickel (II) complexes of substituted ethylenediamines. Depending on the temperature, 
solvent, anions present and other factors, this complex varies widely in color and 
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magnetic properties. This phenomenon is the result of facile and reversible addition of 
ligands at the axial positions of square-planar complexes and changing Ni(II) from 
diamagnetic to paramagnetic. 
Among the over two hundred known Zn2+ proteins, Zn2+ has the preference 
binding to histidine, cysteine and aspartic acid. In most cases, zinc forms four-
coordinated or six-coordinated complexes with ligands. The four-coordinated zinc 
complex prefers tetrahedral stereochemistry, and no square-planar complex has been 
observed. For example, zinc binds thermo lysin by tetrahedrally coordinating three side 
chains, from two histidines, glutamic acid and a water molecule (Lippard and Berg, 1994). 
Glutamic acids commonly function as ligands with common modes of interaction 
illustrated in Figure 33. Glutamic acid can function as a bridging ligand between two 
metal ions, serve as a terminal ligand to one or two ions, or act as a bidentate chelator to 
bind one metal ion. Besides the aforementioned M2L and ML complexes, a ML2 complex 
could be formed by one metal coordinating two ligands. 
Figure 33 Metal binding modes of carboxylate ligand 
a b c 
d e 
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Since an ML complex is the most observed metal ligand adducts in our study 
(Table 8) and the chelator binding (Figure 33e) provides the most stable complex, we 
proposed that two glutamic side chains function as the tetradentate chelator in binding 
divalent nickel or zinc ion. Both Ni(II) and Zn(II) (referred as M(II) or M2+) are four-
coordinate metal ions and binding the tetradentate ligand would satisfy the coordination 
geometry. Center metal zinc should adopt a tetrahedral geometry, and nickel could be 
either square-planar or tetrahedral, as shown in Figure 34. The complex ions [L + M2+_ 
H+t and [L + M2+]2+ observed in the MS study are the same ligand-metal complex 
acquiring one or two protons from the environment. The observed peptide 
E . Nickel . peptide E sandwich complex (NiLl+) could be an equilibrated structure 
among four species as Figure 35 illustrates. In this case interligand metal binding is 
favored over intraligand binding and tetrahedral nickel binds with two chelators provided 
by different ligand molecules. Also, an alternative structure of the NiL/+ complex is 
proposed in Figure 36. The octahedral nickel coordination sphere consists of two 
bidentate carboxylate chelator and two oxygen atoms from the remaining carboxylate 
groups. The definite metal binding mode of NiL2
2+ complex was not determined in our 
study. 
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Figure 34 Proposed structure of the peptide E . metal (ML) complexes (M: Ni2+ or 
Figure 35 Proposed equilibrated structures of the sandwich complex peptide E . Ni . 
peptide E (Ni adopts the tetrahedral structure) 
11 I! 
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Figure 36 Alternative proposed structure of the sandwich complex peptide E . Ni . 
peptide E (Ni adopts the octahedral structure) 
HO 
When Fe3+ binds with peptide E ligand, we observed both Fe(III)H_2L + and 
Fe(III)H_IL2+ complexes. Since iron always adopts a six-coordinated octahedral 
geometry, the iron could be coordinated by tetradentate dicarboxylic acid ligand and two 
water molecules to complete its six-coordination, and the proposed structure is shown in 
Figure 37. 
Figure 37 Proposed coordination structure of the peptide E . Fe (III) complex 
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In summary, in the acidic water/ actonitrile (1:1) solution of peptide E metal 
perchlorate complexes (pH= 5), doubly charged species ML2+ (M: Ni(II) and Zn(II» 
existed as the predominant ligand metal adducts in the form of [Ni2+Lf+ (m/z= 341.8) 
and [Zn2+L]2+ (m/z= 344.7) based on ESI-MS data (Table 8, Figure 38-41). MR\L+ 
complexes were also observed in both peptide E nickel and zinc adducts as [Ne+L - H+t 
(m/z= 682.4) and [Zn2+L - H+t (m/z= 688.4). ML2+ complex could also be present in the 
form of perchlorate salts as [Ni2+L + CI04"t ion (m/z= 782.4) and [Zn2+L + CI04"t 
(m/z= 788) (Figure 39, 41). Other species of metal ligand complex could also exist in the 
system but were not observed in this study. Such unobserved complexes could remain 
uncharged and undetected in MS or the corresponding m/z value could be out of the 




Figure 38 ESI-MS study of the peptide E (L) Ni2+ complex 
(38a (top) Calculated spectrum for C26H37N70IINi; 38b (bottom) Experimental spectrum showing small peaks at 682 (nickel complex) and 
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Figure 39 ESI-MS study of the peptide E (L) . Ni2+complex (higher mass region) 
(39a: Calculated spectrum for CSZH7SN 140zzNi; 39b: Calculated spectrum for CZ6H37N70IlNi; 
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Figure 40 ESI-MS study of the peptide E'(L) Zn2+complex 
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Figure 41 ESI-MS study of the peptide E-(L) Zn2+ complex (higher mass region) 
(41a (top): Calculated spectrum for C26H37N7011Zn; 41b (middle): Calculated spectrum for C26H38N701 sCIZn; 
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Figure 42 ESI-MS study of the peptide E (L)· Fe3+complex 
(42a (top) Calculated spectrum for CZ6H36N7011Fe; 42b (bottom) Experimental spectrum of the peptide E· Fe(III) complex) 
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Figure 43a ESI-MS study of complexes of peptide E (L) with Fe(CI04)3, Ni(CI04)2 and Zn(CI04h 
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(43b: Calculated spectrum for C26H36N701lFe; 43c: Calculated spectrum for C26H37N70IlZn; 43d: Calculated spectrum for C26H37N701lNi; 
43e: Experimental spectrum of complexes of peptide E with Fe(CI04)3, Ni(CI04)2 and Zri(CI04)2) 
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4. Metal Binding Study of Peptide H (Ac-GIYt-Glu2(NHOH)-D-Pro3-
GIY4-Glus(NHOH)-D-Pro6-NH2) with ESI-MS 
As with peptide E, peptide H single metal binding was studied by ESI-MS. 
However, these individual complex spectra gave a rather complicated pattern, since large 
fragment ion peaks were observed, and they were further examined by MS/MS. These 
results will be discussed in the peptide fragmentation section. The data for the peptide H 
metal mixture competitive study was more straightforward and is outlined here (Figure 
44 - 47). In the following section, L refers to the free ligand hydroxamic acid peptide H. 
Based on the need of experiments free ligand (peptide H) was mixed with metal 
ions F e3+, Zn2+ and Ni2+ in different ratios in water-acetonitrile (1: 1) solution. Formic 
acid was added to adjust the pH value to 5. Figure 44 illustrates the ESI-MS spectrum of 
peptide H binding to metal mixtures in different ratios. First, the free ligand was mixed 
with metal salts in the ratio of peptide H: Fe3+: Ni2+: Zn2+= 1: 1: 1: 1, and only an [L + 
Fe3+ - 2H+t ion was observed in the ESI-MS spectrum, which demonstrates that the 
ligand exclusively binds Fe(III). Neither the free ligand, nor peptide H bound with zinc or 
peptide H bound with nickel complex ions was observed. Second a mixture of peptide H: 
Fe3+: Ni2+: Zn2+= 3: 1: 1: 1 was subjected to ESI-MS; in this particular solution enough 
ligand is available for all the metal to bind. Nevertheless, the ESI-MS result demonstrated 
that [L + Fe3+ -2H+t was still the predominant ion while an [L + Zn2+ - wt ion was 
observed only in low intensity, and some free ligand molecular ion was also detected. 
Finally, the peptide H was introduced to a metal salt mixture in which Fe3+ was in very 
low concentration compared to other metals (peptide H: Fe3+: Ne+: Zn2+= 1: 0.1: 1: 1). In 
this experiment, the peak of ion [L + Fe3+ - 2H+t is in similar intensity to the [L + Ni2+ -
89 
H+t peak, and the [L + Zn2+ - H+t ion was twice as intense. Most of the peptide 
remained as a free ligand in this iron deficient environment. Then the peptide H was 
introduced in a mixture where Ni2+ and Zn2+ were in large excess compared to Fe3+ 
(peptide H: Fe3+: Ni2+: Zn2+= 1: 1: 10: 10), and only a peptide H . Fe(III) adduct was 
observed in this case (Figure 45). This observation demonstrated that peptide H binds 
Fe(III) to a much greater extent than Zn(II) or Ni(II) and the peptide H . Fe(III) complex 
is outstandingly stable. Fe(III) could not be replaced by divalent Zn(II) and Ni(II) ions in 
this experiment, even the divalent ions existing in much higher concentrations. 
This hypothesis was further strengthened by the final experiment in this series. 
Peptide H was mixed with Ni(CI04)2 and Zn(CI04)2 in the ratio of 1: 1: 1 and free 
peptide, peptide H . Ni(II) and peptide H . Zn(II) peaks were observed in a ratio of 1: 1: 
1.2 (relative peak abundance ratio) (Figure 46, top spectrum) in ESI-MS study. Then one 
equivalent Fe(CI04)3 was introduced to the mixture, and, as shown in Figure 44 top 
spectrum, only peptide H . Fe(III) complex was detected (Figure 46, bottom spectrum). 
Therefore, no matter what the sequence of metal introduction to the ligand, the ligand 
showed a predominant preference for Fe(III), which can replace the pre-adducted metal 
thoroughly and effectively. Based on the ESI-MS experiment data obtained in these 
competitive metal binding exams, we conclude that metal binding preference of peptide 
His Fe3+» Zn2+> Nf+ at pH = 5. 
To study the pH effect on peptide H metal binding behavior, we carried out one 
of the competitive metal binding experiments under more acidic conditions (pH = 2). 
After comparing the ESI-MS spectra obtained at different pH values (Figure 47), we did 
not observe any major changes of peptide H metal selectivity, and the peptide H iron 
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complex was still found to be the almost exclusive ligand-metal species. Therefore the 
dihydroxamic acid peptide was shown to be a very selective siderophore analogue with 




Figure 44 Metal binding selectivity test of peptide H (L) and metal mixtures in different ratios 
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Figure 45 Metal binding selectivity test with peptide H (L) and metal mixtures (peptide H: Fe3+: Ni2+: Zn2+ = 1:1 :10:10) 
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Figure 47 ESI-MS of peptide H (L)-Fe3+-Ni2+_Zn2+ (1:1:1:1) at pH~5 vs pH~2 
709,1 [L + Fe3+ - 2H+r 
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5. Peptide Fragmentation (Tandem MS/ MS) 
The types of fragment ions observed in an MSIMS spectrum depend on the 
primary sequence, the amount of internal energy, how the energy was introduced and 
charge state. In low energy CID (collision induced dissociation) study, a peptide carrying 
fragments with positive charge one mainly along its backbone, generates predominantly 
sequential ions. A fragment is only detected if it carries at least one charge. Johnson 
modified the nomenclature of the fragment ions proposed by Roepstorff and Fohlman 
(Roepstorff and F ohlman, 1984) by defining the ion as either a, b or c when the charge is 
retained on the N terminal fragment, or either x, y or z when the charge in retain on the C 
terminal fragment. The cleavage can occur between a C-C bond, giving a and x ions, 
between a C-N bond, giving band y ions, or between a N-C bond, giving c and zions 
(Figure 48) (Johnson, 1988). Subscripts indicate the number of residues in a fragment. 
For example, the following peptide containing four amino acid residues could be 
fragmented into a)-a3, b)-b3, C)-C3, X)-X3, Y)-Y3 and Z)-Z3, as eighteen ions in total. 
Fragmentation of peptide E (Ac-G)E2dP3G4EsdP6-NH2) was studied by tandem 
MSIMS. Based on the detected fragment ions shown in Figure 49, we proposed that the 
sites of peptide chain cleavage included the amide bonds between Glu2-Pro3, Pro3-GlY4, 
GlY4-Glus and Glus-Pro6, and these cleavages could provide eight fragment ions (Figure 
50). Five fragments were clearly detected and assigned with certain structures, but the b2, 
Y2 and Y3 fragments were not observed. We found the amide bonds between Glu and Pro 
are the most fragile bonds in peptide E, since the detection of bs, y), Y4 is the result of 
amide bond scission of Glus-Pro6 or Glu2-Pro3. The fact that the tertiary proline amide 
96 
could be transferred to the more stable secondary amine after the bond scission, could 
explain the bond scission between Glu and Pro. 
Figure 48 Peptide fragment nomenclature 
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The fragment with a mass of 284 was shown as the most significant peak among 
the daughter peaks of 626 (Figure 49); however, this mass did not belong to any C-
tenninal or N-terminal fragment of peptide E based on the peptide fragment 
nomenclature described in Figure 48. We boldly proposed that the fragment with a mass 
97 
of 284 could be generated from a double cleavage of peptide E. If the amide bonds 
between Glu2-Pr03 and Glus-Pro6 could be cleaved simultaneously, three fragments 
would be generated including Ac-GlYI-Glu2 (b2), Pro6-NH2 (yl) and Pr03-GlY4-Glus 
(with a mass of 284). Although no evidence of double cleavage to a peptide chain has 
been reported yet, we still could rationalize our proposal based on the unique properties 
of our peptides. Peptide E contained repetitive amino acids including two prolines in the 
sequence. In the process of ionization, the amide bonds between Glu2 and Pr03 and Glus 
and Pro6 are the equally most fragile links in the peptide, which has also been proven by 
other fragmentation routes of peptide E (Figure 50). Because of these similar properties, 
two amide bonds could be cleaved at the same time and provide three fragments 
including b2 and yl and fragment 284 (proposed as PGE) (Figure 51). Later we did the 
fragmentation study of peptide H, which is the hydroxamic acid analogue of peptide E 
and also contains the repetitive sequence involving Glu-Pro. Similar results were 
obtained in peptide H system, which further verified this double fragmentation proposal. 
The fragment ion with a mass of 256 could originate from the fragment with a 
mass of 284 (PGE) by losing a water molecule (Figure 49). The fragmentation study of 
peptide E illustrated the weakest link in peptide E and demonstrated the possible 
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Figure 50 Proposed fragmentation route of peptide E (Ac-GEdPGEdP-NH2) 
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Figure 51 Proposed double cleavage route of peptide E 
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yl (m/z= 115) 
The CID experimental results for both free peptide H (Ac-
GIE2(NHOH)dP3G4Es(NHOH)dP6-NH2) and peptide H plus individual metals are 
summarized in Table 10 and Figure 52. The daughter peaks of peptide H molecular mass 
peak (m/z= 656) include fragment ions peaks shown at 542, 509, 413, 380 and 299. As 
with peptide E, the amide bond between Glus(NHOH) and Pr06 appears to be the most 
readily cleaved giving [AC-GIE2(NHOH)dP3G4Es(NHOH)t (bs) with a mass of 542 and 
[Pro-NH2t (Yl) with a mass of 115 (Figure 54). We assume that the fragment ion bs can 
self-cyclize into a more stable N-hydroxysuccimide cation, which also has a mass of 542, 
thus both linear or cyclic ions can account for fragment 2 observed in MSIMS (Figure 
55). Fragment 3 appeared to be the result of fragment 1 (linear or cyclized form) losing 
an NHOH group on either the Glu2(NHOH) or Glus(NHOH) residue by path 1, 2 or 3 
(Figure 55). Therefore, there could be three kinds of ions matching the mass of 509 
(Fragment 3) as shown in Figure 55. In this self-cyclization process the glutamine 
backbone N could attack its glutamine hydroxamate side chain carbonyl group, followed 
by elimination of the NHOH group, resulting in the formation of a stable five-membered 
lactam ring. 
The amide bond cleavage between Glu2(NHOH) and Pro3 provided fragment 6 
and fragment 12. For fragment 6, the glutamic acid backbone N could attack its 
hydroxamate side chain carbonyl group, and NHOH group was the leaving group, 
resulting in the final formation of lactam fragment ion 8 (Figure 56). 
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Figure 52 ESI study of peptide H with varying ionization voltages providing fragments for MS/ MS analysis 
(top spectrum, daughter peaks of the peptide H molecular ion peak (m/z= 656); 
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Figure 56 Proposed fragmentation path of peptide H to generate fragments 6 and 12 through cleavage 
between E2(NHOH) and P3 and fragment 8 via fragment 6 side chain cyclization 
amide bond breaking between E2(NHOH) and P3 
to gives b2 and Y 4 ions 
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All the observed daughter peaks of peptide H molecular ion peak (mlz= 656) 
except the peak with a mass of 299 have been assigned with respective fragment ions. In 
determining the structure of fragment 10 (mlz= 299), we compared the fragment ions of 
peptide E and peptide H and discovered that fragment 10 in peptide H could be the 
counterpart of double cleavage fragment PGE (mlz= 284) in peptide E. 
We observed that mass 299 could be mass 284 plus 15 (NH), that fragment 10 
(m/z= 299) must have the same amino acid composition as its glutamic acid analogue 
fragment ion with a mass of 284, and have CONHOH group instead of COOH on 
glutamic acid side chain. Fragment ion with a mass of 284 was proposed as fragment ion 
[P3G4Est in peptide E. Similarly, we deduced that fragment 10 (mlz= 299) could be the 
product of double fragmentation including ion [G1E2(NHOH)P3t, [E2(NHOH)P3G4t, 
[P3G4Es(NHOH)t, [G4Es(NHOH)P6t and [CH3CO-Es(NHOH)P6-NH2t the C-terminal 
residue after GlY4 N-C bond cleavage. All of these fragments have the desired mass 
(m/z= 299). 
The precursor (parent)-ion MSIMS was utilized in tracking the parent peaks of the 
defined fragment peak. Fragments with masses of 413, 542, 656, 701 and 741 were 
identified as the parent peaks of the ion with a mass of299 (Figure 52, bottom spectrum). 
Fragments with the masses of 701 and 740 could be the peptide E metal adducts, which 
existed in the parent peptide sample, and will be discussed in detail. The fact that ion 
ptG4Es(NHOH)P6 (Fragment 6, m/z= 413) could produce fragment 10 (mlz 299) is a 
clear evidence that fragment 10 should include C-terminal GlY4 and Glus(NHOH) in the 
tripeptide sequence. Therefore, we can eliminate the possibility of tripeptides 
G1E2(NHOH)P3 and E2(NHOH)P3G4 as fragment 10. The identification of fragment 10 
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(Figure 57) was achieved through fragmentation study of fragment 10. 
Figure 57 Structure ofPGE(NHOH), GE(NHOH)P and CH3CO-E(NHOH)P-NH2 
PGE\NHOH) GE\NHOH)P 
Among the daughter fragments of fragment 10, the fragments corresponding to a 
proline immonium ion (m/z= 70) and a glutamic acid satellite ion (m/z= 145) were 
detected in Figure 58. We also observed a fragment with a mass of 126.9, representing 
the residue Pro-N+H=CH2. Fragment ion Pro-N+H=CH2 is the product of glycine C-C 
bond cleavage in fragment 10, which illustrated the existence of P-G sequence in 
fragment 10. Neither the double cleaved fragment G4Es(NHOH)P6 nor the N-C bond 
cleaved fragment CH3CO-Es(NHOH)P6-NH2 contains the sequence Pro-Gly, and only 
two kinds of tripeptide, E2(NHOH)P3G4 and P3G4E5(NHOH), can generate residue Pro-
N+H=CH2. Since the sequence G4E5(NHOH)P6-NH2 had already been eliminated as a 
possible structure by an earlier peak MS/MS study, we concluded that fragment 10 was 
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P3G4ES(NHOH). The MS/MS study of daughter peak of fragment 10 also supported this 
conclusion. 
Fragment P3G4Es(NHOH) could be obtained from the pathway described in 
Figure 59. After simultaneous amide bond cleavage between Glu2·Pro3 and Glus·Pr06, 
fragment ions with a mass of 244 and 115 would have been generated in addition to 
fragment 10. We detected the fragment ion with a mass of 115 by MSIMS (Figure 53, 
lower mass region); however, the peak at 244 was not among peptide H daughter peaks. 
Nonetheless, we observed a peak with the mass of 244 in low relative abundance among 
daughter peaks of the species with a mass of 701 (one of the peptide H adducts) (Figure 
60), and we can assume that the fragment ion with a mass of 244 originated from peptide 
H as ion b2. Therefore, all fragment ions generated in this pathway were detected in 
peptide H and peptide H adduct MS/MS experiments, which could be used as a solid 
evidence to support the proposed structure of fragment 10. This conclusion is consistent 
with the double fragmentation product P3G4ES (m/z= 284) in peptide E, and this unique 
double fragmentation has not been reported in any published literature to the best of our 
knowledge. The ,uniqueness of our system involving two proline residues in symmetric 
sequence can explain this significant double fragmentation. The amide bonds betw'een 
prolines and glutamic acids were the most easily broken sites in peptide E and H, which 
was demonstrated previously. Instead of being the unstable tertiary amide bond, the 
double cleavage could generate two more stable secondary amine residues, which could 
be the driving force of double cleavage for peptide E and H. The similar double cleavage 
was also observed in the peptide H metal complexes system, which will be discussed 
later. 
! 10 
In conclusion, the amide bond between glutamic acid and proline was the most 
fragile bond in both peptide E and peptide H, and the simultaneous cleavage of two of 
these bonds generated fragment P3G4ES or P3G4Es(NHOH) from peptide E or H. It is 
worth noting that fragment P3G4ES(NHOH) is the smallest detected and identified metal 
binding fragment for peptide H and bears only one metal binding site. Therefore, the 
detection of fragment 10 metal complex could enable us to locate the stronger metal 






























Figure 59 Proposed fragmentation path to give fragment ion with a mass of299 
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Table 10 ESI-MS data from CID individual fragments of peptide H 
(Ac-GlYIGlu2(NHOH)dPro3GlY4Glus(NHOH)dPro6-NH2), 
along with the metal (Ni(II), Zn(II) and Fe(III» adducts 
Mass Peptide H + Ha Peptide H + N?+ b Peptide H + Zn2+ c Peptide H + Fe3+ d 
Fragment 
Difference (656) (712) (718) (709) 
-33 679 685 
2 -114 542 598 604 595 
3 -147 509 565 571 
4 -149 560 
5 -189 520 
6 -243 413 469 475 466 
7 -275 434 
8 -276 380 436 442 
9 -291 427 
10 -357 299 355 361 352 
a: reference Figure 53a; b: reference Figure 64b; c: reference Figure 65b; d: reference Figure 68 
(bottom spectrum) 
In the ESI-MS spectrum of peptide H (Figure 53, top spectrum), we found an 
unassigned peak with a mass of 701 detected with significant height. To verify that the 
ion with a mass of 701 originated from peptide H, we perfonned a MS/MS study of peak 
701 and found its fragment peaks (Figure 60) are in almost the same pattern as the 
daughter peaks of 656 (Figure 53, bottom spectrum). Thus, the peptide species with a 
mass of 701 was in the same peptide sequence as peptide H. We first proposed that this 
peptide species should contain peptide H adducted with two sodium ions (structure 1 in 
Figure 61), which has the correct mass but one more charge and did not agree with m/z 
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equaling of 701. We also suggested the structure 2 with the deprotonated NHOH group 
and the peptide H sodium complex bearing an overall positive charge of one but with a 


































Possible structures of the molecular ion with a mass of701 
Structure 1 Structure 2 
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6. Peptide H • Metal Adducts Fragmentation 
Next we studied the peptide metal complex fragmentation by ESI-MS to locate 
the metal binding site of the hydroxamate peptide (Figure 64 - 66). L was used to refer 
the free ligand hydroxamic acid peptide H, and M referred to divalent cation Ni(II) or 
Zn(II). 
Divalent cation nickel and zinc provided similar pattern of fragments in CID 
experiments. Hydroxamate peptide H has two metal binding sites, and both glutamic acid 
hydroxamate side chains could be deprotonated and come toward to each other to form a 
tetradentate binding pocket to hold the divalent cation ([L + Ne+- H+t (m1z = 712) and 
[L + Zn2+-H+t (m1z = 718» (Figure 62). However, one arm may have the stronger 
binding of the metal, which will be discussed later. 
In peptide H metal adducts fragmentation routes, the C-terminal cleavage of Pro-
NH2 group could give fragment 2 . M2+ ions (Figure 62). Upon ionization one 
hydroxamate group underwent self-cyclization to lose the NHOH metal chelator group, 
and only one hydroxamic acid group remained as bidentate ligand donor towards the 
divalent cation, the binding mode of which is depicted as fragment 3 . Ni(II) or Zn(II) 
complexes (Figure 62). 
As mentioned before, the peptide chain of free peptide H could have cleaved 
between Glu2(NHOH) and Pro3 and provided the sequence [Pr03-GI14(NHOH)-Glys-
Pro6-NH2t (fragment 6 (m1z= 413» (Figure 64, spectrum 3). In the case of the peptide 
metal complex, peaks at 469 (Figure 64, spectrum 2) and 475 (Figure 65 spectrum 2) are 
the fragment 6 Pr03-GI14(NHOH)-GlYs-Pro6-NH2 binding with Ni2+ and Zn2+ separately. 
Since the N-terminal fragment Ac-GlYI-Glu2(NHOH) (m1z= 244) did not show up as 
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adducts with metal ions in the CID experiment of peptide H nickel or zinc complexes, we 
concluded that after the amide bond scission, the metal stayed with C terminal peptide 
fragment instead of N terminal peptide fragment. This result suggested that Ni(II) and 
Zn(II) bind C -terminal Glu5(NHOH) more tightly than N-terminal Glu2(NHOH). The 
double fragmentation of peptide H . Zn(II) or Ni(II) complexes was observed in the same 
mode of free ligand peptide H. The detection of fragment 10 (P3G4E5(NHOH)) . M(II) 
complexes is a clear evidence that the C-terminal metal binding site has stronger metal 
binding capability than the N-terminal metal binding site (Figure 63). Fragment 8 could 
be generated through side chain cyclization of fragment 6; however, due to the 
unavailability of hydroxamic acid side chains, we could not· determine the metal binding 
mode of fragment 8 . M(II) complex. The fragment with a mass of 427 was observed as 
one of the peptide H . Zn(II) complex daughter peaks, and the assignment of this peak is 
still under investigation. 
The coordination structure of the peptide H fragment ion adducting with metal 
complexes is not well understood in our study. We proposed that the zinc and nickel in 
these fragment metal complexes would retain the same tetrahedron coordination 
geometry that solution phase metal possesses. In peptide H and fragment 2 metal 
complexes, M(II) binds with two bidentate hydroxamate chelators to form the four-
coordinated metal complex (Figure 62). Since fragments 1, 3, 6 and 10 only have one 
hydroxamate metal chelator, Ni(II) and Zn(II) have to bind two more ligands to satisfy a 
tetrahedron geometry. The vacant coordination site ofNi and Zn metal could be occupied 
by solvent molecules, which were eliminated in the ionization process in gas phase and 
gave only the mass of a peptide fragment and a metal ion. Alternatively, other functional 
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groups besides the hydroxamic acid side chain could coordinate the central metal (zinc or 
nickel) in these fragments (fragment 1, 3, 6 and 10) to provide a four-coordinate metal-
ligand complex, and the details of the structure remained unclear. Overall the peptide H . 
M(II) complexes (M: Ni(II) and Zn(II» experienced similar fragmentation processes to 
free peptide H. Although only one hydroxamate metal binding site remained in the 
ligand, one hydroxamate group still functioned as the potent chelator in binding divalent 
cation Zn(H) and Ni(H). 
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Figure 62 Proposed fragmentation route for the peptide H M(l!) complex (L: free peptide H, M: Ni or Zn) 
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Figure 63 Continued Proposed Fragmentation route for the peptide H . M(II) complex (M: Ni or Zn) 
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Figure 64 ESI-MS and MSIMS studies of peptide H· Ni(U) vs MS/MS study of free peptide H 
(64a: ESI-MS spectrum of peptide H . NiCII), 64b: cm experiment of peptide H . Ni(II) molecular ion peak and 










Peptide H ,NiH 
714,0 
o '" "'~, I i FI"I"~:~ f), I rrl.\ tit I rat.,')" , i1>t'f~i , Ii., i at, , rl J i~ i ,.1*. i 1 , i i~i .'1 ; i • i Pi i Ai. pit, i • f; 4l. i ' 
100 355,1 
Fragment 10, Ni2+ 
0/0 
Fragment 6 ' Nj2+ 
469,2 
Fragment 3 ' NiH 
Daughters of712ES+ 
5.91e6 
Fragment 2 ' Ni2+ Peptide H ' Ni2+ 
712,3 565,2 598,3 
















I 0 ' ~ 6 I ,J I ri , i : iii ii' , , ii' , 1 iii' , i ' r i ; iii: iii' , , ii' iii' '.: i , , • ii' i ; ii' , Iii e , : , i , ; 1 , i • i , iii , eLi iii ii' mlz 






Figure 65 ESI-MS and MSIMS studies of peptide H . Zn(II) 
(65a: ESI-MS spectrum of peptide H· Zn(II), 65b: cm experiment of peptide H· Zn(II) molecular ion peak and 
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A single hydroxamic acid group behaves as a typical bidentate donor towards 
various metal ions, and the bihydroxamic acids in our system could function as 
tetradentate ligands to bind Ni and Zn. Being a trivalent ion. Fe(III) usually participates 
in a six-coordinate complex with octahedral geometry. Hydroxamate type siderophores 
generally possess two or three hydroxamate functional groups, which are able to form 
stable hexacoordinate iron (III) complexes (FeL or Fe2L3, respectively). For example, 
alcalign is a 20 membered macrocylic dihydroxamate siderophore, which forms a 1: 1 
ferric complex (FeL +) under acidic conditions and 2: 3 ferric complexes (Fe2L3) at and 
above neutral pH (Hou, 1998). The tetradentate ligand does not assume the preferred 
octahedral coordination geometry of Fe (III) by forming a simple 1:1 complex. In order 
to completely encapsulate the metal ion, a dihydroxamate siderophore must at minimum 
form a binuclear metal complex with a stoichiometry ofF~L3. 
In this study, dihydroxamic acid peptide H was mixed with ferric ion in a 1: 1 
ratio in water/acetonitrile solution at pH 5 and formed a FeL + complex, which was 
detected as an ion [L . Fe3+_ 2H+t (L: peptide H) with a mass of 709 in ESI-MS (Figure 
66). The center Fe atom could octahedrally coordinate with two C-O oxygens, two N-O 
oxygens from peptide H and two solvent molecules (Figure 67). The two solvent 
molecules could be detached from the metal in the process of ionization; therefore, we 
just observed iron binding with peptide H complex in MS study. 
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Figure 66 ESI-MS study of peptide H . Fe(III) 
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We also studied the peptide H . Fe(III) complex fragmentation process and found 
some similarities between peptide H . Fe(III) fragmentation route and peptide H . Ni(II) 
and peptide H . Zn(lI) fragmentation pathes. For example, the C-terminal amino acid 
cleavage occurred in both the peptide H· Fe(III) complex (Figure 69) and the peptide H . 
Ni(II)/Zn(II) complex (Figure 69 and Table 10). The amide bond cleavage between 
Glu2(NHOH) and Pro3 was also observed in peptide H iron complex and provided 
fragment 6 iron adduct in an MS/MS study. In the complex P3G4ES(NHOH)P6-NH2 . 
Fe(III) (m/z =466), the metal iron stayed in the C-terminal peptide fragment, which 
demonstrates that the C-terminal binding site Glus(NHOH) has the stronger iron-
chelating capability than the N-terminal binding site Glu2(NHOH). This observation is 
consistent with what we found in nickel and zinc complexes. The double fragmentation is 
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represented by the complex molecular fragment 10· Fe(III) (with a mass of 352) and 
shows that the C-terminal binding site is the major chelator in the dihydroxamate ligand 
peptide H. However as it was shown in Figure 69, the fragment iron complexes 
coordination structure was not determined in our study. The vacant coordination site of 
the center Fe atom could be occupied by the solvent molecule in water/ acetonitrile 
solution before ionization with the octahedral geometry being lost in the gas phase to 
provide the complexes (Figure 69) and thus resulting in the complexes having partially 
encapsulate central iron atom. 
Figure 67 Proposed structure of peptide H . Fe (III) 
Among the daughter peaks of fragment 709, the peaks at 560, 520 and 434 are 
remained unassigned. First, we confirmed that all of the peaks are peptide fragments 
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binding with Fe(III) by comparing the MS/MS spectra of complex with a mass of 709 
and a mass of 707 (one of the isotopes of the peptide H . Fe(III) adduct) (Figure 68). All 
the counterparts of peaks at 560, 520 and 434 in MS/MS study of the complex with a 
mass of 709 were observed with less than two masses among daughter peaks of 707. We 
tentatively assigned the fragment with a mass of 434 as fragment 8 adducting with Fe(III), 
which has the formula C17H24FeNsOl+ with the mass 434.11 (Figure 69). Obviously, this 
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Figure 69 Proposed structure of peptide H (L) . F e3+ and the resulting fragments 
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D. Conclusion 
In this study we designed and synthesized two acetylated amidated symmetric 
hexapeptides with two carboxylic acids or two hydroxamate functional groups as metal 
chelators. The preparation was carried out by using solid phase peptide synthesis and the 
hydroxamate functionall groups were introduced by condensing side chain acids with 0-
benzylhydroxylamine. ESI-MS proved to be an efficient tool to study peptide metal 
selectivity, which could not be clearly interpreted in earlier MALDI-TOF MS 
experiments. An MS/MS study was used to locate the stronger metal binding site between 
the two metal chelating groups in one ligand. 
In a peptide competitive metal binding study, we did not observe any significant 
preference of peptide E (diacid) towards cations Fe(III), Ni(II) and Zn(II) (Figure 43 a 
and e). However, metal selectivity studies of bihydroxamate peptide H demonstrated that 
the chelators were almost exclusively selective to Fe(III) in the presence of Ni(II) and 
Zn(II), and the selectivity was pH independent in the range of pH 2~5 (Figure 4447). 
In the ESI-MS spectra of peptide H . Ni(II) and peptide H . Zn(II) , the free 
peptide H peak was observed with significant intensity. A large number of fragment ion 
peaks were also found in addition to the peptide H metal complex peak (Figure 64 and 
Figure 65). These fragments were generated upon ionization with a voltage between 4-5 
e8 and belonged to daughter peaks of both free peptide H and peptide H metal complexes. 
A much simpler spectmm was obtained in the peptide H . Fe(III) MS study (Figure 66), 
since no free ligand pt~ak was observed and only one fragment peak was detected in 
addition to the complex molecular ion peak. The Fe(III) . peptide H complex survived a 
much stronger voltage (9.26 e8) in the process of ionization than other complexes did. 
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Therefore, the conclusion could be drawn that peptide H formed a much more stable 
complex with Fe3+ than with Ni2+ or Zn2+, and peptide H thus has a significant preference 
to Fe(III) compared to Zn(II) or Ni(II), as previously seen in the competitive metal 
binding studies. 
By utilizing the ESI-MS/MS technique, the most fragile amide bonds in the 
hexapeptides peptide E and peptide H (free ligands) were determined to be located 
between glutamic acid and proline. These bond scissions provided C-terminal fragment 
(Ac-Gly-Glu-D-Pro-Gly-Glu + or Ac-Gly-Glu(NHOH)-D-Pro-Gly-Glu l, N-terminal 
fragment (D-Pro+-Gly-Glu-D-Pro-NH2 or D-Pro+-Gly-Glu(NHOH)-D-Pro-NH2) and a 
double cleavage produced the fragment D-Pro-Gly-Glu+ or D-Pro-Gly-Glu+(NHOH) for 
peptide E and peptide H (Figure 50, 51, 56 and 59). Also, an intramolecular cyclization (-
NHOH) involving the hydroxamate side chain was verified in an MS/MS study (Figure 
52, Table 10). 
Fragmentation of the hydroxamic acid containing peptide H . Ni(II) and peptide H 
Zn(II) followed a similar pathway as the free ligand peptide H, except that the 
intramolecular cyclization (-NHOH) was not always accompanied by bond scission 
(Figure 62, Table 10). Vie also proposed that the C-terminal Glu(NHOH) metal chelation 
strengthens the amide bond between Glus-Pro6 to some extent; and therefore, N-terminal 
glutamic hydroxamate side chain cyclization occurs before Glus-Pro6 bond cleavage. In 
the ESI-MS spectra of peptide H . Ni(II) and peptide H . Zn(II), an N-terminal fragment 
and a double cleavage fragment were observed once again in concern with metal binding. 
Since only one metal binding site, Glus(NHOH), exists in these fragments, this result 
demonstrated that the C-terminal binding site (Glus(NHOH)) has a stronger chelation 
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capability than the N terminal (Glu2(NHOH)) metal binding site in peptide H, when this 
ligand binds to Ni(II) or Zn(II). 
The peptide H- Fe(III) complex showed a more complicated fragmentation 
pathway. Only some elements of the fragmentation of the complex could be explained in 
this study. The Glu-Pro amide bond scission was observed to provide a C-terminal 
fragment and an N-terminal fragment, as well as the double cleavage fragment. This 
observation enabled us to locate the stronger iron chelator site as we have seen for nickel 
and zinc. However, no hydroxamate side chain cyclization was observed with the iron 
complex, which can be explained by the fact that the hydroxamate ligand binding Fe(III) 
complex is more stable than the divalent ions adducts. 
In general, it is dear that the hydroxamate peptide has a very high selectivity for 
Fe(IlI) over Zn(II) and Ni(II), and the potential of the peptide to strongly bind other 
trivalent metal ions besides iron can be studied in future work. The symmetry of the 
model peptide chain use:d for these studies led to some difficulties in fragment sequence 
determination and metal binding site location. This problem could be overcomed by 
introducing isotopically labeled amino acids to assist in the analysis if the fragment from 
multiple metal binding sites is found in the same ligand. 
E Experimental Section 
Instruments and materials 
The NU-Boc-protected amino acids, NU-Fmoc-protected amino acids and BOP 
coupling reagent were purchased from Advanced Chern Tech (Louisville, KY). HOBt 
was from Quantum Technologies and TF A was from Halocarbon Products Corp. The 
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pMBHA resin (1.2meq/g) was a gift from Peptides International (Louisville). DMF was 
the solvent used in coupling reaction and was purchased from Fisher and distilled by 
standard protocol before usage. 
The RP-HPLC analysis was performed on a Hitachi 655A system, which was 
equipped with L-5000 controller and D-200 integrator. A Vydac 4.6-250mm CI8 column 
was used for analytical HPLC with detection at 220nm. The peptides were eluted with a 
linear acetonitrile/water gradient with a constant concentration of TF A (0.05% v/v) and 
the separations were monitored by UV detector set at 220nm. HF cleavage of peptides 
from resin was carried out in a Kel-F HF apparatus (Peptide Institute, Osaka). The 
sequence of the peptides was verified by MALDI-TOF MS. Peptide metal binding 
experiments were carried out using both matrix-assisted laser desorption ionization -
time of flight (MALDI-TOF) spectrometer (Voyager-DE™ Pro) and a micromass quarto-
LCZ triple-quadrupole mass spectrometer (ESI-MS). 
1. Synthesis of Ac-Gly-Glu-D-Pro-Gly-Glu-D-Pro-NH2 
(1) Preparation of Boc-D-Pro-MBHA resin (3) 
Prior to the addition of the first amino acid to the solid support, the MBHA resin 
(3 g, 3.6 mmol) was swelled in 20 mL DIEAlDMF (1 :9) solvent for 30 min. DMF was 
then filtered off. An anhydrous DMF solution (25 mL) of Boc-D-Pro-OH (3.10 g, 14.4 
mmol), BOP (6.37 g, 14.4 mmol) and HOBt (1.95 g, 14.4 mmol) was charged with DIEA 
(5 mL, 28.8 mmol). The mixture was introduced to the pre-swollen resin in the reaction 
vessel and allowed to shake for I h. Afterwards the solvent was removed, and the resin 
was washed with DMF (3 x I min), MeOH (3 x Imin) and DCM (3 x I min). A 
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ninhydrine (Kaiser test) showed the complete loading of Boc-D-Pro-OH to the resin and 
the resin ready for future coupling. 
(2) Preparation of Gly-Glu-D-Pro-MBHA resin (4) 
The entire batch of resin 3 (1.2 meq/g; approximate 3 g) was treated with 30 mL 
50% TF A (TF AlCH2Cb/anisole: 50/45/5) for 30 min to deprotect the Boc group. Next 
Boc-Glu(OBn)-OH (4.86 g, 337.4 mmol) and Boc-Gly-OH (2.52 g, 175.2 mmol) were 
coupled to the resin by following the traditional Boc cycle (Chapter 1 Table 5). The N -
terminal protecting group (tert-butyloxycarbonyl group) on glycine was removed by TFA 
again and the resin was dried and split for further reaction. 
(3) Preparation of Ac-Gly-Glu-D-Pro-Gly-Glu-D-Pro-MBHA resin (5) 
A portion of the tripeptide-resin (4) (2.0 g, 1.8 mmol) was used for the next step, 
and Boc-D-Pro-OH, Boc-Glu(OBn)-OH and Boc-Gly-OH were coupled to the resin 
successively using the standard protocol as described in Table 5. After removing N-
terminal Boc group with 50% TF A, the resin was stirred in 15 mL acetic acid and 7 mL 
DIEA in 10 mL DCM. The success of the acetylation of the resin was again monitored by 
a Kaiser test. The resin was washed with DCM and dried in vacuo overnight. 
(4) Preparation of Ac-Gly-Glu-D-Pro-Gly-Glu-D-Pro-NH2 (1) 
In a Kel-HF reaction vessel, 1.5 mL of anisole was added along with 2.4 g of 
dried resin 5 and the resin was cleaved by anhydrous HF at 0 °C. The solid was washed 
with ether to remove organic byproducts and anisole, and the cleaved peptide was 
extracted with 25% acetic acid. After lyophilization 570 mg white powder was obtained. 
Yield: 48%. 
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2. Synthesis of Ac-Gly-Glu(NHOH)-D-Pro-Gly-Glu(NHOH)-D-Pro-NH2 
(1) Preparation of Fmoc-Gly-Glu(O-tBu)-D-Pro-Gly-Glu(O-tBu)-D-Pro-
MBHA resin (6) 
First, MBHA resin (l g, 1.2 mmol, substitution= 1.2 meq/g) was swelled in 
DIEAlDCM: 119 overnight. Next, the different Fmoc amino acid building blocks, Fmoc-
D-Pro-OH (1.23 g, 3.6 mmol), Fmoc-Glu(tBu)-OH (1.53 g, 3.6 mmol), Fmoc-Gly-OH 
(1.07 g, 3.6 mmol), Fmoc-D-Pro-OH (1.23 g, 3.6 mmol), Fmoc-Glu(tBu)-OH (1.53 g, 3.6 
mmol), Fmoc-Gly-OH (1.07 g, 3.6 mmol) were coupled to the resin one by one by 
following the Fmoc cycle as shown in Table 5. Reagents including BOP (1.53 g, 3.6 
mmol), HOBt (0.49 g, 3.6 mmol) and DIEA (1.26 mL, 7.2 mmol) were used in every 
coupling cycle for the condensation reaction. . 
(2). Preparation of Ac-Gly-Glu(O-tBu)-D-Pro-Gly-Glu(O-tBu)-D-Pro-MBHA 
resin (7) 
The N-terminal Fmoc protected hexapeptide resin 6 was treated with 25% 
piperidinelDMF for 30min followed by wash with DMF, MeOH and DCM. The peptide 
wasacetylated on its N-terminus by shaking with 3.4 mL (36 mmol) acetic anhydride and 
6.3 mL (36 mmol) DIEA in 20 mL DCM overnight. 
(3). Preparation of Ac-Gly-Glu(NHOBn)-D-Pro-Gly-Glu(NHOBn)-D-Pro-
MBHA resin (8) 
Starting with the acetylated peptide resin 7, the t-Butyl groups on the glutamic 
acid side chains were removed using three treatments of 30 mL 70% TF A 
(TF AlCH2Ch/anisole: 70/25/5) for 30 min each time. The resin was neutralized by using 
10% DlEAlCH2Ch (3 x 1 min) and washed with DCM and MeOH. 0-
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benzylhydroxylamine (1.15 g, 7.2 mmol) was recovered from NH20Bn • HCI by stirring 
in DMF with DIEA (1.2 mL, 7.2 mmol). Coupling reagents BOP (3.19 g, 7.2 mmol), 
HOBt (0.97 g, 7.2 mmol) and DIEA (1.2 mL, 7.2 mmol) were added to the resin along 
with NH20Bn and the suspension was stirred for two hours. The resin was washed and 
dried in vacuo. 
(4) Preparation of Ac-Gly-Glu(NHOH)-D-Pro-Gly-Glu(NHOH)-D-Pro-NH2 
(2) 
The dry hydroxamate peptide resin 8 was put into a Kel-F HF apparatus and 
stirred with 10 mL anhydrous HF and 0.05 mL anisole at 0 °C for 1 h. HF was 
evaporated and the solid was washed with 20 mL ether three times. The resin was dried 
in air before the peptide was extracted with 25% acetic acid. The crude peptide (390 mg) 
was obtained after lyophilization from aqueous acetic acid. The crude peptide was 
purified through a C-18 column using a step gradient from 2%-8% acetonitrile at 2% 
increments and the desired product was eluted at 8% acetonitrile. Purified peptide (200 
mg) was obtained, and it gave a positive hydroxamate test, changing FeCl) solution from 
yellow to red. Yield: 28%. 
3. General Proeedure for Metal Binding Studies 
Individual metal binding test: The peptide and a metal perchlorate were mixed in 
50 /ll deionized water to provide a 1: 1 equivalent (0.6 /lmol) solution. The aqueous 
solution was mixed with one equivalent acetonitrile and formic acid was added to adjust 
pH to 5 before it was applied directly to ESI-MS. The aqueous solution was mixed with 
a-cyano-4-hydroxycinnamic acid matrix in water (0.1 % TF A): acetonitrile (1:2) solution. 
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Competition metal binding study: The peptide and metal perchlorate mixtures 
with the desired ratios were dissolved in 50 III deionized water in different equivalents 
according to the experimental needs. The aqueous solution was mixed with one 
equivalent acetonitrile and the pH value was adjusted to 5 by adding formic acid and the 
solution was applied directly to ESI-MS. 
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amino succinic acid 
t-butyloxycarbonyl 




collisionally activated decomposition 
collision cell 

































diisopropy lethy lamine 
dimethylformamide 
1-(3 -Dimethy laminopropy 1)-3-ethy 1- carbodiimide hydrochloride 






































milliequivalent per dry gram 
MALDI-TOF MS Matrix Assisted Laser Desorption Ionization - Time of Flight Mass 
Spectrometry 







NaHC03 sodium biCarbonate 


























nuclear magnetic resonance 
nitrilotriacetic acid 
proline 
negative logarithm of hydrogen ion activity 
phenylalaine 




reverse phase-high performance liquid chromatorgraphy 
retention time 
senne 
sodium dodecylsulfate-polyacrylamide gel electrophoresis 
senne 
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